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sails an uncharted sea,
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ABSTRACT
Background
Cardiovascular disease is the most common cause of death in patients with type 1 diabetes
(1), and the premature mortality rates are especially high in patients with diabetic
nephropathy (2, 3). Diabetic retinopathy is the leading cause of vision loss among the
working-age population in industrialized countries (4). Early identification and aggressive
treatment of risk factors are crucial to reduce the incidence of diabetic complications.
Aims
To examine the relationships between lipid profiles and diabetic nephropathy, diabetic
retinopathy, and incident coronary artery disease (CAD) events in a large nationwide
cohort of patients with type 1 diabetes.
Subjects and methods
These studies are part of the ongoing Finnish Diabetic Nephropathy Study (FinnDiane), a
nationwide, multicenter study aimed at identifying both genetic and clinical risk factors
for the development of diabetic complications in patients with type 1 diabetes.  Studies I
(N=2927) and III (N=1465) have a cross-sectional design. At follow-up, renal status was
verified by a review of all available medical files, including laboratory data (Study II,
N=2304), and data on CAD events were retrieved from the Finnish Hospital Discharge
Register and the Causes of Death Register (Study IV, N=3520). Ophthalmologic data from
fundus photographs and ophthalmic records were graded with the Early Treatment of
Diabetic Retinopathy Study (ETDRS) scale (Study III).
Results
Triglycerides and apolipoprotein (Apo) B were independently associated with estimated
glomerular filtration rate (eGFR) in the multivariate models. The recommended lipid
concentrations of current treatment guidelines were poorly met, especially regarding the
target for LDL cholesterol. Triglycerides and ApoB were independent predictors of
progression to micro- and macroalbuminuria, and total cholesterol was an independent
predictor of progression to end-stage renal disease. HDL and HDL2 cholesterol were
independently associated with proliferative diabetic retinopathy (PDR), and triglycerides
and triglyceride/HDL cholesterol ratio with mild non-proliferative diabetic retinopathy
(NPDR). In patients with moderate to severe NPDR or PDR, the correlations between
albumin excretion rate (AER) and lipid variables were strong. However, in patients
without retinopathy no significant correlations were observed. In multivariate models,
ApoB, triglycerides, non-HDL cholesterol, ApoB/ApoA-I ratio, and triglyceride/HDL
cholesterol ratio were the strongest lipid predictors of an incident CAD event.
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Conclusions
Lipid abnormalities were associated with an increased risk of all three diabetic
complications studied, i.e. diabetic nephropathy, retinopathy, and incident CAD events.
Triglycerides and ApoB were independently associated with AER and eGFR and
predicted the progression to micro- and macroalbuminuria as well as incident CAD events.
Far lower concentrations of triglycerides than the currently recommended cut-off level
(<1.7 mmol/l) increased the risk of progression of renal disease and predicted incident
CAD events. Total and LDL cholesterol were poor predictors of an incident CAD event in
patients with normal AER, in patients with HbA1c below the median of the cohort, and in
women, in whom the ratios of atherogenic and anti-atherogenic lipoproteins and lipids
performed better. Current treatment recommendations may need to be revised to reflect
residual CAD risk in patients with type 1 diabetes.
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TIIVISTELMÄ (ABSTRACT IN FINNISH)
Tausta
Sydän- ja verisuonitaudit ovat yleisin kuolinsyy tyypin 1 diabeetikoilla (1), ja
ennenaikainen kuolleisuus on erityisen suuri potilailla, joilla on diabeettinen munuaistauti
eli nefropatia (2, 3). Diabetekseen liittyvä silmäsairaus, retinopatia, on sokeutumisen
yleisin syy länsimaiden työikäisessä väestössä (4). Riskitekijöiden varhainen
tunnistaminen ja tehokas hoito ovat ratkaisevassa asemassa jotta voisimme vähentää
diabeettisten liitännäissairauksien syntyä.
Tavoitteet
Tavoitteina oli tutkia veren rasva-arvojen ja diabeettisen nefropatian, retinopatian, ja
sepelvaltimotautitapahtumien (ensimmäinen sydäninfarkti, sepelvaltimoiden
pallolaajennus tai ohitusleikkaus) yhteyttä suuressa valtakunnallisessa tyypin 1 diabetes-
populaatiossa.
Aineisto ja menetelmät
Tutkimukset ovat osa FinnDiane-tutkimusta (Finnish Diabetic Nephropathy Study), jonka
tavoitteena on selvittää tyypin 1 diabeteksen liitännäissairauksien geneettisiä ja kliinisiä
riskitekijöitä. Osatyöt I (N = 2927) ja III (N = 1465) ovat poikkileikkaustutkimuksia.
Seurantatutkimuksissa tieto munuaistaudin vaikeusasteesta varmennettiin kaikista
käytettävissä olevista sairaskertomuksista (osatyö II, N = 2304), ja tiedot
sepelvaltimotapahtumista saatiin hoitoilmoitusjärjestelmästä (HILMO) sekä
kuolinsyyrekisteristä (osatyö IV, N = 3520).
Tulokset
Hoitosuositusten mukaiset kolesterolipitoisuudet ylittyivät monella potilaalla ja erityisen
huonosti toteutuivat LDL-kolesterolin suositukset. Kohonneet triglyseridi- ja
apolipoproteiini (Apo) B-pitoisuudet ennustivat varhaisen nefropatian (mikroalbuminuria)
sekä nefropatian (makroalbuminuria) kehittymistä. Korkea kokonaiskolesteroli oli
itsenäinen riskitekijä loppuvaiheen munuaistaudin kehittymiselle. Matalat HDL- ja HDL2-
kolesterolipitoisuudet olivat yhteydessä proliferatiiviseen diabeettiseen retinopatiaan
(PDR), ja koholla oleva triglyseridipitoisuus sekä triglyseridi/HDL-kolesterolisuhde olivat
yhteydessä lievään taustaretinopatiaan (NPDR). Potilailla, joilla oli kohtalainen tai vaikea
NPDR tai PDR, korrelaatiot veren rasvojen ja virtsan albumiinierityksen (AER) välillä
olivat vahvoja, mutta vastaavia korrelaatiota ei havaittu lainkaan potilailla, joilla ei ollut
merkkejä retinopatiasta. ApoB, triglyseridit, ei-HDL-kolesteroli, ApoB/ApoA-I-suhde
sekä triglyseridi/HDL-kolesterolisuhde olivat vahvimpia sepelvaltimotautitapahtuman
ennustajia tyypin 1 diabeetikoilla.
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Päätelmät
Epäsuotuisat veren rasva-arvot olivat yhteydessä kaikkiin kolmeen tutkittuun
diabeteskomplikaatioon, eli diabeettiseen nefropatiaan, retinopatiaan, ja
sepelvaltimotautiin. Koholla olevat triglyseridi- ja ApoB-pitoisuudet ennustivat
munuaistaudin etenemistä sekä sepelvaltimotautitapahtumaa. Jo nykyisiä suosituksia (<1.7
mmol/l) huomattavasti matalampi triglyseridipitoisuus ennusti munuaistaudin etenemistä
ja sepelvaltimotautitapahtumia. Kun potilaat jaettiin ryhmiin sukupuolen, munuaistaudin
tai sokeritasapainon mukaan, kokonais- ja LDL-kolesteroliarvot eivät olleet yhteydessä
sepelvaltimotautitapahtumaan naisilla, potilailla joilla oli normaali AER, eikä potilailla
joilla HbA1c oli alle 8.3 %. Näillä potilailla aterogeenisten ja anti-aterogeenisten
lipoproteiinien suhteet olivat parempia sepelvaltimotautitapahtuman ennustajia. Nykyiset
hoitosuositukset tulisi tarkistaa, jotta mahdollinen suurentunut sepelvaltimotautiriski
tyypin 1 diabeetikoilla havaittaisiin paremmin.
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ABSTRAKT (ABSTRACT IN SWEDISH)
Bakgrund
Hjärt-och kärlsjukdomar är den vanligaste dödsorsaken bland typ 1 diabetiker (1), och den
förtidiga dödligheten är särskilt hög hos patienter med diabetisk njursjukdom, nefropati (2,
3). Diabetisk ögonsjukdom, retinopati, är den vanligaste orsaken till blindhet bland den
arbetsföra befolkningen i västvärlden (4). En tidig identifiering och effektiv behandling av
riskfaktorer har en avgörande betydelse för att minska förekomsten av följdsjukdomar vid
typ 1 diabetes.
Studiens målsättningar
Att undersöka sambandet mellan lipidprofiler och diabetisk nefropati, retinopati och
kranskärlssjukdom (första hjärtinfarkt, ballongutvidgning eller bypassoperation av hjärtats
kranskärl) i en stor landsomfattande kohort av patienter med typ 1 diabetes.
Patienter och metoder
Dessa studier är en del av den pågående FinnDiane-studien (Finnish Diabetic Nephropathy
Study), en landsomfattande, multicenterstudie vars målsättning är att identifiera både
genetiska och kliniska riskfaktorer för utvecklingen av följdsjukdomar vid typ 1 diabetes.
Studie I (N = 2927) och III (N = 1465) var tvärsnittsstudier. Vid uppföljningen
verifierades progression av njursjukdom genom en granskning av alla tillgängliga
sjukjournaler (studie II, N = 2304) och uppgifter om kranskärlssjukdom söktes ur Finlands
patient- och dödsorsaksregister (studie IV, N = 3520).
Resultat
De rekommenderade lipidvärdena i gängse behandlingsöversikter uppfylldes dåligt,
speciellt gällande målsättningen för LDL-kolesterolnivån. Förhöjda triglycerid- och
apolipoprotein (Apo) B-nivåer var oberoende riskfaktorer för utveckling av begynnande
njursjukdom (mikroalbuminuri) samt progression till nefropati (makroalbuminuri).
Förhöjda totalkolesterolkoncentrationer var en oberoende riskfaktor för progression till
terminal njursvikt. Låga HDL- och HDL2-kolesterolnivåer var associerade med
proliferativ diabetisk retinopati (PDR), och triglycerider samt triglycerid/HDL-
kolesterolförhållandet med mild icke-proliferativ diabetisk retinopati (NPDR). Hos
patienter med måttlig till svår NPDR eller PDR, var korrelationerna mellan lipider och
albuminutsöndring i urinen (AER) starka, men bland patienter utan retinopati kunde inga
signifikanta korrelationer observeras. De starkaste lipidprediktorerna för insjuknandet i
kranskärlssjukdom hos typ 1 diabetiker var ApoB, triglycerider, icke-HDL-kolesterol,
ApoB/ApoA-I-förhållandet samt triglycerid/HDL-kolesterolförhållandet.
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Slutsatser
En ofördelaktig lipidprofil var associerad med samtliga av de tre undersökta
diabeteskomplikationerna, dvs. diabetisk nefropati, retinopati, och kranskärlssjukdom.
Förhöjda triglycerid- och ApoB-nivåer förutspådde både progression av njursjukdom samt
insjuknande i kranskärlssjukdom. Betydligt lägre koncentrationer av triglycerider än den
för tillfället rekommenderade nivån (<1.7 mmol/l) ökade risken för progression av
njursjukdom och insjuknande i kranskärlssjukdom bland typ 1 diabetiker. När patienterna
delades in i grupper på basen av kön, graden av njursjukdom eller sockerbalans,
förutspådde inte total- och LDL-kolesterolnivåerna kranskärlssjukdom hos kvinnor,
patienter med normalt AER, eller patienter med HbA1c under 8.3 %. Förhållandet mellan
de aterogena och anti-aterogena lipiderna var betydligt bättre prediktorer för
kranskärlssjukdom hos dessa patienter. Gängse behandlingsrekommendationer för typ 1
diabetiker bör eventuellt revideras för att bättre upptäcka den potentiellt ökade
kranskärlssjukdomsrisken.
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1 INTRODUCTION
Diabetes is one of the most common chronic diseases worldwide, and in 2013 altogether
382 million people were estimated to have diabetes (5). The global prevalence of type 2
diabetes is increasing in epidemic proportions due to an increase in obesity, a low level of
physical activity, and aging of the population. In 2035 a predicted 592 million people will
have diabetes (5). In Finland, ~250 000 individuals have diagnosed type 2 diabetes and
~200 000 are estimated to have undiagnosed type 2 diabetes (6). It is noteworthy that
Finland has the highest incidence of type 1 diabetes in the world (7), with the current
number of patients with  type 1 diabetes being ~50 000 (8). The incidence of type 1
diabetes is also increasing worldwide, but the reasons for this remain unclear (9).
Type 1 diabetes was a fatal disease until the discovery of insulin in 1921. Despite modern
insulin treatment,  glycemic control is  poor in many patients with type 1 diabetes,  and in
the Finnish Diabetic Nephropathy Study (FinnDiane) cohort only ~15% of the patients had
reached the recommended glycosylated hemoglobin A1c (HbA1c) level of <7.0% (10).
With increasing HbA1c, the frequency of diabetic complications also increases
substantially. Diabetic complications lead to reduced quality of life and premature death.
The management and treatment of these complications also cause an immense economic
burden (11).
Diabetic kidney disease (nephropathy) is the leading cause of dialysis or kidney
transplantation (12). Nephropathy develops in about one-third of patients with type 1
diabetes, and the highest incidence peak is seen after 15-20 years of diabetes (13, 14).
Diabetic  eye  disease  (retinopathy)  is  the  most  common  cause  of  blindness  among  the
working-aged population in the Western world (4). Proliferative diabetic retinopathy
(PDR), the advanced form of diabetic retinopathy, occurs in around 40% of patients with
type 1 diabetes after 25 years of diabetes duration (15). Diabetic nephropathy and
retinopathy share several risk factors and are strongly associated with each other (16). The
studies regarding the association between lipid variables and retinopathy have yielded
conflicting results (17-20), and the effect of renal disease on this relationship is unclear.
Also unknown is how retinopathy status affects the association between albumin excretion
rate (AER) and lipid variables.
The most common cause of death in patients with type 1 diabetes is cardiovascular disease
(CVD) (21). The increased incidence of CVD in patients with type 1 diabetes is mostly
related to renal disease, and the mortality rates of patients with type 1 diabetes without any
signs  of  renal  disease  are  comparable  with  those  of  the  general  population,  whereas  in
patients with end-stage renal disease (ESRD) an 18- to 30-fold increase in mortality has
been observed (2, 3). The role of the lipid variables in the development of coronary artery
disease (CAD) has been studied thoroughly in the general population and in patients with
type 2 diabetes, but studies in patients with type 1 diabetes are scarce.
17
The main aim of these series of studies was to evaluate the relationship between lipid
profiles and different diabetic complications, i.e. diabetic nephropathy, retinopathy, and
incident CAD events, in a large nationwide cohort of patients with type 1 diabetes.
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2 REVIEW OF THE LITERATURE
2.1 Types of diabetes mellitus
2.1.1 Definition of diabetes
Diabetes mellitus is a chronic systemic disease characterized by an increased blood
glucose concentration. The word diabetes is derived from the Greek word “diabainein”
and means “to pass through”, referring to the large volume of urine, while mellitus comes
from the Latin term “mel”, which means honey and refers to the sweetness of the urine
from patients with untreated diabetes. Diabetes is caused by either decreased production of
insulin from the pancreatic β-cells or decreased effect of insulin on target tissues or by a
combination of these two. Diabetes not only causes disturbances in carbohydrate
metabolism, but also affects lipid and protein metabolisms. Diabetes is defined as an
increased fasting plasma glucose ≥ 7.0 mmol/l or a 2-h plasma glucose ≥ 11.1 mmol/l
during an oral glucose tolerance test or HbA1c ≥ 6.5% or a random plasma glucose of  ≥
11.1 mmol/l in a patient with classic symptoms of hyperglycemia (thirst, weight loss, and
polyuria) (22-24).
2.1.2 Classification of diabetes
The two major categories of diabetes are type 1 and type 2 diabetes, previously also called
“insulin-dependent” (IDDM) and “non-insulin-dependent” (NIDDM), or “juvenile” and
“adult-onset” diabetes, respectively. Type 1 diabetes is characterized by an autoimmune
reaction that leads to a total loss of function of the insulin-secreting β-cells of the islets of
Langerhans in the pancreas, resulting in absolute insulin deficiency. Type 2 diabetes is the
consequence of decreased insulin sensitivity (primarily in skeletal muscles, adipose tissue,
and liver) and/or decreased insulin secretion from β-cells. It is the most common form of
diabetes and is increasing in epidemic proportions worldwide. Considerable overlap exists
between  the  two  conditions,  and  type  1  and  type  2  diabetes  have  been  proposed  to  be
different forms of the same disease, the main difference being the absence of an immune
response in patients with type 2 diabetes,  leading to a slower rate of β-cell  loss (25).  On
the other hand, the clear lack of evidence for similar genetic factors predisposing to type 1
and type 2 diabetes supports the notion of two separate diseases.
Latent  Autoimmune  Diabetes  of  the  Adult  (LADA)  is  classified  as  a  form  of  type  1
diabetes and is characterized by the presence of islet autoantibodies, most typically
glutamic acid decarboxylase antibodies (GADA), leading to the destruction of pancreatic
β-cells  (26,  27).  Patients  with  LADA  are  usually  older  than  the  patients  with  type  1
diabetes and do not require insulin at  the time of diagnosis,  but after 5 years of diabetes
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duration ~80% require insulin treatment. The clinical phenotype resembles that of type 2
diabetes, and LADA patients may initially be diagnosed as having type 2 diabetes. Due to
the features described above, LADA is sometimes also called “type 1.5 diabetes” or
“slow-onset type 1 diabetes”.
Maturity onset diabetes of the young (MODY) is a heterogeneous group of disorders
caused by mutations in different autosomal dominant genes with high penetration,
affecting insulin production or insulin release from pancreatic β-cells (28). It can also be
referred to as monogenic diabetes, in contrast to the more complex type 1 and type 2
diabetes, which involve multiple genes with low penetration as well as environmental
factors.  MODY  patients  do  not  display  the  β-cell  autoimmunity  or  ketoacidosis
experienced by patients with type 1 diabetes, and the age at onset is usually younger than
in  patients  with  type  2  diabetes.  Typical  characteristics  of  type  1  and  type  2  diabetes,
LADA, and MODY can be seen in Table 1.
 Table 1. Typical characteristics of different forms of diabetes.
IAA=insulin autoantibodies, GADA=glutamic acid decarboxylase antibodies, ICA=islet cell antibodies, IA2-
A=insulinoma-associated autoantigen 2 antibodies, ZnT8A = Zink transporter 8 antibodies.
Gestational diabetes is diagnosed when hyperglycemia is first recognized during
pregnancy and is associated with insulin resistance and increased risk of type 2 diabetes
(29).
Type 1 diabetes Type 2 diabetes LADA MODY
Age at onset Usually age
below 35 years
(highest peak at
puberty)
Usually in adults
over 40 years
(also in obese
children/
adolescents)
Usually age above
30 years
Usually age
below 30
years
Characteristics
of diagnosis
Acute, often
ketosis
Often insidious Symptoms develop
more slowly than in
type 1 diabetes
Variable, many
are
asymptomatic
Insulin level at
diagnosis
Undetectable or
very low
High Low Variable
Presence of
insulin
resistance
Usually no (but
may be present
in obese
patients)
Yes Yes (in some
studies less
common than in
type 2 diabetes)
No (insulin
resistance is
extremely
rare)
Insulin therapy Essential and
permanent
May occur Usually not at
diagnosis, most
need insulin within
5 years
May occur
(insulin doses
are low)
Auto-
antibodies
IAA GADA, ICA,
IA2-A, ZnT8A…
None Mostly GADA and
ICA (IA-2A, IAA,
ZnT8A may be
detected)
None/Rare
Genetics Polygenic Polygenic Polygenic Monogenic
Autoimmune
etiology
Yes No Yes No
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Secondary forms of diabetes can be caused by, for example, pancreatitis, surgery,
pancreatic trauma, and pancreatic cancer. Further, long-term use of such medications as
steroids, antipsychotics, and a range of immunosuppressive agents may induce the
development of diabetes (30). Medications widely used for prevention of CVD, e.g.
thiazide diuretics, beta-blockers, and statins have also been found to be weakly
diabetogenic (30, 31).
2.1.3 Epidemiology of type 1 diabetes
Type 1 diabetes is one of the most common chronic diseases of childhood, and in contrast
to other autoimmune diseases, it has a male predominance (32). The highest incidence of
type 1 diabetes is found in Finland (64 per 100 000 per year below the age of 15) (7),
followed by the Italian island of Sardinia and Sweden (33). The lowest incidence of type 1
diabetes is found in Venezuela and China, with only around 0.1 per 100 000 per year (33).
The incidence of type 2 diabetes is increasing rapidly, mainly because of sedentary
lifestyle and an increase in obesity, but the reasons behind the worldwide increase in the
incidence of type 1 diabetes remain unclear. In Finland, a non-linear increase has been
observed, and the incidence rate of type 1 diabetes in Finnish children has doubled from
1980 to 2005 (7). Recent studies have reported a plateau in the incidence rates in Finland
and Sweden (34, 35). Another recent finding is that the onset of diabetes has shifted
towards a younger age (36, 37), and according to the “spring harvest theory” the
increasing incidence in children might be compensated by a decrease in the incidence in
the older age groups (38). In concordance with this theory, the overall cumulative
incidence of type 1 diabetes before the age of 39 years in Sweden and Belgium has
remained constant (37, 39). However, in Finland the increasing incidence of type 1
diabetes is also seen in the age group of 15-39 years (40); thus, in Finland the “spring
harvest theory” does not seem to apply. Genetic variation is thought to be one explanation
for the marked geographical differences in the incidence rates, but genetic changes and
more children being borne to parents with type 1 diabetes are still insufficient to explain
the increased incidence. Thus, environmental factors must play a role. In support of this,
increased incidence of type 1 diabetes has also been reported in children of migrants who
have moved from a region of low to high incidence of type 1 diabetes (41, 42).
2.1.4 Pathogenesis of type 1 diabetes
Type 1 diabetes involves selective β-cell loss and is the result of an autoimmune reaction.
T-cells (CD8+ and CD4+), macrophages (CD68+), and B-lymphocytes (CB20+) are
frequently found in insulitis lesions (43). Autoantibodies against β-cell autoantigens, e.g.
insulin autoantibodies (IAA), GADA, islet cell antibodies (ICA), insulinoma-associated
autoantigen 2 antibodies (IA-2A), and Zink transporter 8 antibodies (ZnT8A) (44), are
found  in  more  than  90%  of  patients  with  newly  diagnosed  type  1  diabetes  and  they  are
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already present months to years before symptomatic onset. However, only 25-50% of
children with autoantibody positivity will eventually develop clinical type 1 diabetes,
hence, many remain in a subclinical state or the β-cell autoimmunity is aborted (45). Type
1 diabetes is a polygenic disease, and thus far, over 40 loci are known to affect
susceptibility to the disease (46, 47). Most of these loci are believed to involve immune
responses. The highest risk is associated with the human leukocyte antigen (HLA) region
on chromosome 6p21 (48), which accounts for ~50% of the genetic susceptibility.
However, the proportion of high-risk HLA genotypes in newly diagnosed patients has
decreased, and therefore, the influence of the environment is thought to have increased
(49). The true triggers of the autoimmune reaction in genetically susceptible individuals
remain obscure. High birth weight and weight gain in infancy have been suggested as risk
factors for type 1 diabetes, and in the “accelerator hypothesis” increased body mass is
thought to overload the β-cells, with the increased insulin demand accelerating the
autoimmune attack (25). Different dietary factors, such as cow milk (50), potatoes infested
by Streptomyces species (51), gluten (52), and short duration of breast feeding (53), have
been suggested as environmental agents initiating the disease process. Other triggers
might be vitamin D deficiency (54, 55), enteroviruses (56), Cesarean section (57), and gut
microbiota (58). Interestingly, seasonal changes in incidence rates have also been noted.
Being born in the spring is associated with a higher risk (59), and more cases are
diagnosed in the fall and winter (60) at the peak occurrence of enteroviruses and vitamin
D deficiency. The “hygiene hypothesis” suggests that a decrease in infections during
childhood leads to inadequate functioning of the immune system (61). In support of this
theory, a reciprocal trend has been seen between the incidence of infectious diseases and
the incidence of autoimmune and allergic diseases. Furthermore, the incidence of type 1
diabetes is positively associated with the gross national product (62) and is lower in poor
countries with a higher population density (63). Also, a protective effect of exposure to
infections with early daycare attendance has been observed (64). Interestingly, metabolite
and lipid profiles have also been suggested as markers for the development of type 1
diabetes. For example, reduced phosphatidylcholine at birth, and decreased triglycerides
and antioxidant ether phospholipids during the follow-up period were observed in children
who developed diabetes (65). Further, increased levels of proinflammatory
lysophosphatidylcholines were seen months before seroconversion to autoantibody
positivity. Increased odd-chain triglycerides as well as polyunsaturated fatty acid-
containing phospholipids and lower concentrations of methionine have also been observed
in autoantibody-positive children (66).
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2.2 Diabetic complications
2.2.1 Diabetic nephropathy
2.2.1.1 Definition
Diabetic nephropathy is defined as a progressive increase in urinary albumin excretion rate
(AER), and a decline in glomerular filtration rate. AER is measured from a timed urine
collection (either overnight or 24 h). Microalbuminuria is defined as an increase in AER
of ≥20 μg/min or ≥30 mg/24 h. Macroalbuminuria (also called proteinuria or overt
nephropathy) is defined as an increase in AER of ≥200 μg/min or ≥300 mg/24 h. Several
factors can falsely increase AER, e.g. infections, fever, physical exercise, pregnancy,
hematuria, menstruation, congestive heart failure, marked hyperglycemia, or hypertension
(67). Due to variability in AER, at least two out of three consecutive urine collections are
required to define the renal status.  Another method for screening is a spot urine sample
from which the albumin-to-creatinine ratio (ACR) is measured. The cut-off points for
micro- and macroalbuminuria if ACR is used are ≥2.5 or ≥3.5 mg/mmol and >25 or >35
mg/mmol in men and women, respectively. The final stage of diabetic nephropathy is end-
stage renal disease (ESRD), defined as requiring dialysis or a renal transplant.
2.2.1.2 Renal function
Renal function, i.e. glomerular filtration rate (GFR), is classified into five categories by
the Kidney Disease: Improving Global Outcomes (KDIGO): stage 1 (normal) = GFR ≥90,
stage 2 (mildly reduced) = GFR 60-89, stage 3 (moderately reduced) = GFR 30-59, stage 4
(severely reduced) = GFR 15-29, and stage 5 (renal failure) = GFR <15 ml/min/1.73 m2
(68). GFR can be directly measured by the plasma clearance of inulin or the chromium
EDTA method (Cr51-EDTA)  (69,  70).  Unfortunately,  the  direct  measurement  of  GFR  is
laborious and costly, and therefore, not feasible in the routine clinical setting or in studies
with large cohorts. Thus, different mathematical formulas have been developed to
calculate the estimated GFR (eGFR).  The most often used creatinine-based formulas are
the Cockcroft-Gault (71), the Modification of Diet in Renal Disease (MDRD) (72), and
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (73) (see Discussion
in Section 7.5). Creatinine is a waste product of skeletal muscle, and muscle mass
therefore influences creatinine production. It is filtered and mainly secreted by the
glomerulus, however, there is also tubular secretion of creatinine. Cystatin C is produced
at a constant rate and filtered by the kidneys without active tubular secretion, and it has
therefore been suggested as an earlier marker of renal dysfunction than creatinine (74).
However, no consensus exists as to whether or not cystatin C should replace creatinine
measurements. Equations using both creatinine and cystatin C have also been proposed
(75, 76).
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2.2.1.3 Epidemiology
Diabetic nephropathy is the key determinant of morbidity and mortality in patients with
diabetes (2, 77). It is associated with high CVD risk and is also the most common cause of
renal failure in the Western world (12). As diabetes is constantly increasing worldwide,
renal failure is also becoming a growing healthcare problem. The peak incidence of
nephropathy occurs after a 15- to 20-year duration of diabetes (13). It has previously been
shown that around one-third of patients with type 1 diabetes will eventually develop
diabetic nephropathy (78), but more recent studies have demonstrated that the incidence of
diabetic nephropathy has decreased, probably because treatment of the major risk factors
has improved (79).
Microalbuminuria is still the best non-invasive predictor of diabetic nephropathy. In
patients with diabetes duration of over 15 years, 28% progressed to macroalbuminuria
during a 10-year follow-up (80), whereas in earlier studies up to 80% progressed (81, 82).
Regression from microalbuminuria to normal AER is not unusual and has varied from
around 30% (13, 80) to as high as 58% in one study (83). Initially, it was thought that in
patients with microalbuminuria decline in GFR does not occur (apart from the yearly
decline in GFR that results from aging, which is ~1 ml/min/year in individuals over 40
years of age). However, in a cohort from the Joslin Diabetes Center a progressive decline
in GFR estimated by cystatin C was observed in 31% of patients with microalbuminuria
(84).
After the onset of macroalbuminuria, the average GFR decline is around 10-12
ml/min/year without treatment of hypertension, and hence, the development of ESRD
would take around 8-10 years (85, 86). Fortunately, efficient treatment of hypertension
will slow down the development of ESRD and even regression from macroalbuminuria to
normal AER is possible. In a Finnish study, the cumulative incidence of ESRD was lower
than previously reported, 7.8% after 30 years of diabetes duration, and the prognosis of
type 1 diabetes was more favorable in patients diagnosed in the more recent years (87).
The increase in AER and the decrease in GFR do not always go hand in hand. In the
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) cohort the cumulative incidence of stage 3 chronic kidney
disease (CKD, eGFR <60 ml/min/1.73 m2) was 11.4%, and out of these patients 24% were
normoalbuminuric, 16% microalbuminuric, and 61% macroalbuminuric (88). The decline
in eGFR was 1.2%/year and 5.7%/year in normoalbuminuric and macroalbuminuric
patients, respectively.
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2.2.1.4 Pathogenesis
Diabetic nephropathy in patients with type 1 diabetes leads to morphological changes in
renal arterioles, tubules, interstitium, and, most importantly, the glomerulus.
Glomerulopathy, with thickening of the glomerular basement membrane and mesangial
expansion, is a hallmark of diabetic nephropathy (89). Glomerular basement membrane
thickening occurs first and can be observed as early as 2 years after the onset of diabetes
(90). Mesangial expansion, mostly due to an increase in the mesangial matrix, can be
observed already after 5-7 years of diabetes onset (91). Diffuse mesangial expansion is
associated with the pathognomonic nodular lesions called Kimmelstiel-Wilson nodules
(92). Glomerular and tubular basement membrane thickening as well as mesangial
expansions are consequences of increased accumulation of extracellular matrix
components, e.g. type IV collagen, fibronectin, and laminin (93, 94). Different stages of
mesangial expansion and the development of Kimmelstiel-Wilson nodules result in
glomerulosclerosis (95). Arteriolar hyalinosis, i.e. exudative lesions in which plasma
proteins (e.g. immunoglobulins, fibrinogen, and albumin) may ultimately replace smooth
muscle cells, may be present a few years after onset (91, 96). Abnormalities of the
glomerular-tubular junction are a late manifestation of the disease (97). In advanced
diabetic nephropathy, also tubulointestinal injury, such as inflammation, atrophy, and
fibrosis, is observed (98).
It is likely that interactions between several risk factors contribute to the development and
progression of diabetic nephropathy. Figure 1 illustrates how hyperglycemia,
hypertension, inflammation, and dyslipidemia could lead to the activation of various
pathways implicated in the pathogenesis of diabetic nephropathy. Potential pathogenic
mechanisms behind lipid-induced renal injury are also discussed in Section 2.3.5.
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Figure 1. A simplified overview of the various possible pathways implicated in the pathogenesis
of  diabetic  nephropathy.  Glyc  =  glycated,  ox  =  oxidized,  ROS  =  reactive  oxygen  species,  RNS  =
reactive nitrogen species, AGE = advanced glycation end-products, RAGE = receptor of advanced
glycation end-products,  PKC = protein kinase C, ACE =  angiotensin-converting enzyme, TGF-β =
transforming growth factor beta, VEGF = vascular endothelial growth factor, PDGF = platelet-
derived  growth  factor,  CTGF  =  connective  tissue  growth  factor,  TNF-α =  tumor  necrosis  factor
alpha,  IL  = interleukin, MCP = monocyte chemotactic protein, M-CSF = macrophage colony-
stimulating factor, ICAM = intercellular adhesion molecule, VCAM = vascular cell adhesion
molecule.
2.2.1.5 Risk factors
Glycemic control
Long-term glycemic exposure is a prerequisite for the development of diabetic
nephropathy, and several studies have demonstrated that poor glycemic control increases
the  risk  of  progression  of  renal  disease  (99-101).  In  the  Diabetes  Control  and
Complications Trial (DCCT), the development of microalbuminuria was reduced by 39%
and  progression  to  macroalbuminuria  by  54%  in  patients  with  type  1  diabetes  with  an
HbA1c ~7% relative to those with HbA1c ~9% (102). In the post-trial follow-up, the risk of
macroalbuminuria was still significantly reduced in the intensively treated group despite
similar HbA1c levels after the trial period, suggesting that glycemic memory exists (103).
In patients with type 2 diabetes, the United Kingdom Prospective Diabetes Study
(UKPDS, HbA1c 7.0% vs. 7.9%), the Action in Diabetes and Vascular Disease
(ADVANCE, HbA1c 6.5%  vs.  7.3%),  and  the  Veterans  Affairs  Diabetes  Trial  (VADT,
HbA1c 7.3% vs. 9.3%) have all shown a reduction in microvascular end-points and other
beneficial effects of intensified glycemic control (104-106). However, the Action to
Control Cardiovascular Risk in Diabetes (ACCORD, HbA1c 6.3% vs. 7.6%) Trial, which
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aimed to reduce HbA1c below 6.0%,  had  to  be  discontinued  after  3.7  years  into  the  trial
due to excess mortality in the intensive treatment group (107). Intensive and rapid
decrease of the HbA1c can lead to increased risk of hypoglycemia and weight gain, and
individualization of treatment goals is thus now emphasized. Large glycemic variability
has also been shown to predict progression of both micro- and macroalbuminuria (108,
109).
Blood pressure
Blood pressure increases in parallel with the increase in AER and is positively correlated
with the decline in GFR (110-112). Notably, antihypertensive agents, such as
Angiotensin-Converting Enzyme (ACE) inhibitors and Angiotensin II Receptor Blockers
(ARBs), have shown renoprotective effects independently of their blood pressure-lowering
effects (113, 114). For patients with type 1 diabetes, more evidence of the beneficial effect
of ACE inhibitors on diabetic nephropathy prevention is available, and recently a meta-
analysis also showed that ACE inhibitors reduce all-cause mortality and major CVD
events in patients with diabetes (115), whereas no beneficial effects on these parameters
were seen with ARB treatment. Therefore, ACE inhibitors are the first line of treatment
for blood pressure reduction in patients with type 1 diabetes. However, most patients need
multiple antihypertensive agents to reach the blood pressure treatment targets. Dual
blockade with both ACE inhibitors and ARBs has been proposed, but it has raised safety
concerns and is not widely recommended. Epidemiological analyses have shown that
systolic blood pressure (SBP) >120 mmHg predicts the development of ESRD in the long
term, and therefore, a treatment goal of <130/80 mmHg was recommended for patients
with diabetes (116). However, recent guidelines have changed the treatment goals back to
the less stringent goal of <140/80 mmHg due to lack of evidence of beneficial effects with
lower SBP targets (117). In the ACCORD Trial, intensified blood pressure treatment (119
vs. 134 mmHg) reduced albuminuria rates and stroke events, but no beneficial effects
were seen on other CVD events or renal function (118). In fact, there was an increase in
serious adverse events (e.g. syncope and hyperkalemia). A meta-analysis of 14
randomized clinical trials yielded similar results and concluded that an SBP goal between
130 and 135 mmHg is acceptable (119). These trials included patients with type 2 diabetes
with a mean age between 55 and 67 years. An SBP target of <130 mmHg may still be
appropriate in younger patients, especially if the target can be achieved with fewer drugs
and without side-effects.
Insulin resistance
Insulin  resistance  is  not  only  observed  in  patients  with  type  2,  but  is  also  a  common
feature in patients with type 1 diabetes and is observed mainly in the peripheral and
hepatic tissues (120). The golden standard for measuring insulin sensitivity is the
euglycemic hyperinsulinemic clamp technique (121). Using this technique, insulin
resistance was shown to predict the development of microalbuminuria in one study (122),
while another found no association between AER and insulin sensitivity (123). Use of the
euglycemic hyperinsulinemic clamp is, however, laborious and invasive. Therefore, larger
studies have used a surrogate estimate for insulin sensitivity, the estimated glucose
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disposal rate (eGDR), which was developed by Williams et al. (124). Notably, in the
Pittsburgh Epidemiology of Diabetes Complications (EDC) cohort the eGDR predicted
progression to macroalbuminuria (125). Further, in the FinnDiane cohort metabolic
syndrome, which is strongly associated with insulin resistance, predicted renal disease
progression (126), and having a first-degree relative with type 2 diabetes increased the risk
of diabetic nephropathy (127).
Genetics
Diabetic nephropathy clusters in families (128), and in genetically similar patient groups
(e.g. Pima Indians, Mexican Americans, Asians, New Zealand Maoris, and Australian
Aborigines), the development of diabetic nephropathy is much more common than in
individuals of white European origin (129, 130). Therefore, it is likely that genetic factors
cause susceptibility to the development of diabetic nephropathy. However, thus far, the
results have been a bit disappointing, and very few specific associations between gene
variants and diabetic nephropathy have been found. Genes suggested but not shown to be
conclusively associated with diabetic nephropathy include e.g. angiotensin-converting
enzyme (ACE), engulfment and cell motility 1 (ELMO1), vascular endothelial growth
factor (VEGF), apolipoprotein E (APOE), apolipoprotein C-I (APOC-I), and
erythropoietin (EPO). To date the largest genome-wide association study, including the
FinnDiane  cohort,  is  the  Genetics  of  Nephropathy  -  an  International  Effort  (GENIE)
Consortium, which identified an intronic single-nucleotide polymorphism (SNP) in the
v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 (ERBB4) gene  to  be
nominally  associated  with  diabetic  nephropathy  (131).  While  this  association  was  not  of
genome-wide significance, the effect was consistent in all cohorts. It is of note that ERBB4
encodes a tyrosine kinase receptor and is involved in tubular development (132).
Smoking
Smoking has been shown to increase the risk of development and progression of diabetic
nephropathy in patients with type 1 or type 2 diabetes (133). The pathogenic mechanism is
thought to be a deleterious effect of smoking on vascular endothelial cells.
Other risk factors
Other suggested risk factors for diabetic nephropathy are e.g. long diabetes duration (134),
male sex (13), anemia (135, 136), low birth weight (137), short adult stature (138), high
protein diet (139), adiponectin (140),  advanced glycation end-products (AGEs) (141),
inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) (142),
and lipid variables. The role of the lipid profile in the development of diabetic
nephropathy is discussed at length in Sections 7.1 and 7.2. Several studies have explored
the associations between lipid variables and renal disease (143-146); however, whether the
lipid abnormalities precede or occur concomitantly with the increase in AER is still under
debate. Furthermore, how retinopathy status affects the association between AER and lipid
variables is also unknown.
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2.2.2 Diabetic retinopathy
Diabetic retinopathy is a feared complication and the leading cause of adult onset
blindness in the working-aged population in the Western world (4). The advanced form of
diabetic retinopathy, proliferative diabetic retinopathy (PDR), is sight-threatening and
characterized by the proliferation of abnormal new, fragile blood vessels in response to
ischemia and vitreous hemorrhage (Figure 2). PDR is preceded by non-proliferative
diabetic retinopathy (NPDR), which is classified into different stages depending on the
presence and severity of microaneurysms, hemorrhages, retinal edema, lipid exudates,
intraretinal microvascular abnormalities (IRMAs), and microinfarcts. A detailed
classification of diabetic retinopathy was developed by the Early Treatment of Diabetic
Retinopathy Study (ETDRS) (147) in the 1980s and it has become the golden standard to
define the severity of diabetic retinopathy.
Figure 2. Fundus photograph of proliferative diabetic retinopathy with neovascularization
(thin arrow) and an occluded artery (thick arrow) as well as scatter laser scars.
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Diabetic macular edema involves leakage and exudation at the center of the eye (macula)
and may lead to impairment of central vision (Figure 3). Macular edema is more common
in elderly patients and therefore also more common in patients with type 2 diabetes. It can
be divided into mild (some retinal thickening or hard exudates in the posterior pole, but
distant from the center of the macula), moderate (retinal thickening or hard exudates
approaching the center of the macula, but not involving the center), and severe (retinal
thickening or hard exudates involving the center) (148). Macular edema is generally
asymptomatic at early stages, but if it progresses it can cause severe visual disability,
especially in older patients (149).  It  is  the most common cause of visual loss in patients
with type 2 diabetes (150).
Figure 3. Fundus photograph of macular edema with hard exudates (=lipid breakdown
products due to vascular leakage=thin arrow) and intraretinal hemorrhages (thick arrow).
2.2.2.1 Epidemiology
With a sufficiently long duration of diabetes, nearly all patients with type 1 diabetes will
eventually have some degree of diabetic retinopathy (15, 151), however, the rate of the
progression and the severity of retinopathy varies substantially. The most profound
increase in the incidence of PDR is usually seen after a 10 year duration of diabetes (152).
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A number of studies have looked at the prevalence and incidence of diabetic retinopathy,
but the results have been very conflicting due to differences in methodology (153). In the
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), a population-based
study including 995 patients with type 1 diabetes, the 25-year cumulative incidence of any
retinopathy was 97%, and the incidence of PDR was 42% (15). Due to improved
management of diabetes and related risk factors, a reduction in the incidence of
retinopathy has been noted in recent studies. In a meta-analysis including patients with
diabetes without ocular treatment for retinopathy at baseline, the 4-year incidence of PDR
in studies performed before and after 1985 was 19.5% and 2.6%, respectively (154). Also
in the FinnDiane cohort, a reduction in the cumulative incidence of severe diabetic
retinopathy over the last decades has been observed (155).
Prompt laser treatment is  crucial  for the prevention of severe vision loss in patients with
PDR (156).  However,  laser treatment destroys retinal tissue,  and the desired result  is  not
always achieved, and sometimes treatment is initiated too late. Therefore, comprehensive
screening and treatment and recognition of risk factors are crucial for the prevention of
diabetic retinopathy.
2.2.2.2 Risk factors
Hyperglycemia is the most important modifiable risk factor for prevention of diabetic
retinopathy. Strong evidence indicates an association between poor glycemic control and
worsening of diabetic retinopathy and between improved glycemic control and favorable
outcome. The first long-term study conducted for the period 1947-1973 followed 4398
patients with diabetes and showed that poor glycemic control assessed cumulatively over
the years is related to a higher incidence and progression of retinopathy (157). In the
DCCT Study, intensified glycemic control in patients with type 1 diabetes for a mean of
6.5 years resulted in a 47% reduction of the risk of severe NPDR or PDR (158). Further,
intensified treatment reduced the incidence of retinopathy by 76% and slowed down the
progression of retinopathy by 54% in patients with retinopathy at baseline. With HbA1c
above 6.5%, there is a clear increase in the prevalence of retinopathy, which partly also
explains why this threshold has been chosen for the diagnosis of diabetes (23).
Paradoxically, a transient worsening of diabetic retinopathy is seen if the glycemic control
improves too rapidly, a phenomenon called “early worsening” (159, 160), and similarly as
for the diabetic nephropathy progression, large variability of the HbA1c was a risk factor
for diabetic retinopathy in both the DCCT (108) and the FinnDiane cohort (161).
Elevated blood pressure is associated with the progression of diabetic retinopathy in
patients with type 1 diabetes (162), and antihypertensive treatment is associated with
slower progression of diabetic retinopathy. In the UKPDS Trial, including hypertensive
patients with type 2 diabetes, tighter blood pressure control (defined as <150/85 mmHg)
resulted in a 35% reduction in the need for laser treatment and 25% less patients with a
≥2-step  progression  on  the  ETDRS  severity  scale  (163).  In  the  EURODIAB  Study,
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treatment with an ACE inhibitor, lisinopril, in patients with type 1 diabetes reduced
diabetic retinopathy progression by 50% after only 2 years of follow-up (164). Further,
treatment with an ARB, candesartan, also reduced the incidence of diabetic retinopathy in
patients with type 1 diabetes (165) and increased regression of diabetic retinopathy in
patients with type 2 diabetes (166). However, no additional benefits from intensively
lowered blood pressure targets (SBP <120 mmHg) have been found (167).
Duration of diabetes is the strongest non-modifiable risk factor for diabetic retinopathy.
After a 5-year duration of diabetes, the prevalence of diabetic retinopathy is only 17%,
whereas in those with ≥15 years it is as high as 97.5% (168).
Pregnancy causes a transient increase in the risk of diabetic retinopathy, but fortunately
the long-term risk of diabetic retinopathy seems to be unaffected (169, 170).
Smoking has also been associated with the progression of diabetic retinopathy, however,
the results have been somewhat inconsistent and suggested to be mediated through the
poorer glycemic control observed in smokers (171, 172).
Other risk factors associated with retinopathy are e.g. anemia (173), waist-hip ratio
(WHR) (174), recent cataract surgery (175), puberty (176), and heavy alcohol
consumption (177). Dyslipidemia has also been suggested to be a risk factor for diabetic
retinopathy, but previous studies have yielded conflicting results (17-20). In fact, most
studies to date have reported a lack of an association between lipid variables and diabetic
retinopathy (178), leading to the conclusion that traditional lipid variables are most likely
not related to diabetic retinopathy.
Diabetic nephropathy and retinopathy are strongly associated with each other and share
several risk factors and mechanisms of disease progression (16). Micro- and
macroalbuminuria are strongly associated with diabetic retinopathy, especially in patients
with younger age at onset (179). However, renal status has been unknown or not taken into
account in most retinopathy studies, and thus, comparison between studies is problematic
when the prevalence of renal disease has most probably varied between the studied
cohorts. The interactions between diabetic retinopathy, nephropathy, and lipid variables
have also not been studied previously. How these interactions affect the associations
between complications and lipid variables is thus unknown.
2.2.3 Diabetic neuropathy
Diabetic neuropathy is the most common form of neuropathy in industrialized countries,
and in clinical practice the simple definition of “the presence of symptoms and/or signs of
peripheral nerve dysfunction in people with diabetes after the exclusion of other causes”
(180) can be used. The prevalence of diabetic nephropathy increases with longer diabetes
duration and has been reported to be around 50% after 15-20 years of diabetes (181),
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although large variation is present in the prevalence estimates between studies. Screening
for neuropathy is recommended 5 years after the onset of type 1 diabetes, after which an
annual examination is advised (117). Distal symmetric polyneuropathy (DPN) is the most
common form of diabetic nephropathy (182), and clinical tests for its detection include
vibration sensation assessment, monofilament perception, and ankle reflex testing. Around
one-third of all patients with diabetic neuropathy suffer from unpleasant sensory
symptoms such as pain, numbness, burning sensation, or tingling (183). A wide range of
medications, e.g. pregabalin, venlafaxine, duloxetine, gabapentin, amitriptyline, valproate,
and opioids is  used to treat  neuropathic pain (184),  which is often,  however,  resistant to
treatment. No specific treatment for the underlying nerve damage is available, except
improved glycemic control, which has been shown to prevent the development and
progression of the disease (185). The symptoms can also be diminished by avoidance of
extreme fluctuations  in  blood  glucose  levels  (117).  Up to  half  of  the  patients  with  DPN
may be asymptomatic, however, due to loss of sensation they have an increased risk of
foot injury. Foot ulcers are often initiated by diabetic neuropathy and together with
peripheral arterial disease, neuropathy is the major underlying cause of diabetic foot ulcers
and  amputation  of  lower  extremities,  which  cause  suffering  and  disability  and  are
laborious and costly for the healthcare system (186).
Diabetic autonomic neuropathy can cause e.g. exercise intolerance, orthostatic
hypotension, gastroparesis, constipation, diarrhea, erectile dysfunction, loss of bladder
control, silent ischemia, impaired sweat gland innervation, and decreased response to
hypoglycemia.  Cardiovascular autonomic neuropathy (CAN) can be detected by changes
in heart rate variability and an abnormal response to deep breathing, standing, and the
Valsalva maneuver. An advanced stage of CAN is indicated by resting tachycardia (pulse
>100/min) and orthostatic hypotension (i.e. a decrease in SBP [20 mmHg] or diastolic
blood pressure [DBP, 10 mmHg] after standing up without an appropriate heart rate
response) (117). CAN is an independent risk factor for cardiovascular mortality (187), and
a multifactorial intervention targeting hyperglycemia, hypertension, smoking,
dyslipidemia, and other lifestyle risk factors has been shown to reduce the development
and progression of autonomic neuropathy in patients with type 2 diabetes (188).
2.2.4 Macrovascular complications
Cardiovascular disease (CVD) is the major cause of death in patients with type 1 diabetes
(21). The main clinical features of CVD are coronary artery disease (CAD), stroke, and
peripheral vascular disease. The risk of cardiovascular morbidity and mortality is at least
2- to 4-fold higher in patients with type 2 diabetes than in the general population (189,
190). The risk has previously been considered to be of similar magnitude in patients with
type 1 diabetes, but recent studies have shown that the additional mortality risk is strongly
connected to the renal status. In the FinnDiane cohort, patients with type 1 diabetes with a
normal AER showed no excess in mortality beyond that of the general population,
whereas microalbuminuria was associated with a 3-fold, macroalbuminuria with a 9-fold,
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and ESRD with an 18-fold increase in all-cause mortality (2). The results have later been
replicated in the Pittsburgh EDC cohort with a 20-year follow-up period (3). The reason
for the strong association between CVD and diabetic nephropathy remains unknown. The
two complications share several risk factors and are thought to develop in parallel, but it
can also be argued that CVD develops as a consequence of the hypertension,
inflammation, and dyslipidemia caused by diabetic nephropathy.
The most well-known risk factors for both CVD and diabetic nephropathy are
microalbuminuria, decrease in GFR, age, duration of diabetes, hypertension, glycemic
control, obesity, insulin resistance, smoking, genetic predisposition, and dyslipidemia
(130). The reports on hyperglycemia as a risk factor for CVD have been conflicting, and
glycemic control may be more important for microvascular than macrovascular
complications.  However, glycemic control predicts coronary artery calcification (CAC),
and in the DCCT/EDIC Study, intensive glycemic treatment was associated with less
atherosclerosis in the period after the original trial (191, 192). Moreover, in a Finnish
study, an increment in HbA1c of 1% increased CVD mortality by 52.5% (95% confidence
interval [CI] 28.4–81.3) in patients with type 1 diabetes and by 7.5% (4.3–10.8) in patients
with type 2 diabetes (193).
2.2.4.1 Coronary artery disease
Type 1 diabetes is associated with earlier onset and faster progression of atherosclerosis
(1, 194). Carotid intima-media thickness, which is considered a surrogate marker for early
atherosclerosis, is increased in patients with type 1 diabetes and is similar to the levels of
healthy control subjects who are 20 years older (195). Further, in an earlier study, 35% of
patients with type 1 diabetes died of CAD by age 55, compared with only 8% and 4% of
non-diabetic men and women, respectively (196). In a more recent study, the standardized
mortality rates from CAD were 9 times higher in men and 42 times higher in women with
type 1 diabetes under the age of 40 years (197). The protective effect of female sex is lost
in women with type 1 diabetes, which leads to the higher standardized mortality rates
observed in women in several studies (193, 196, 197). Type 1 diabetes is also associated
with a higher frequency of asymptomatic CAD and as many as 24% of asymptomatic
patients with type 1 diabetes between 35 and 60 years of age have ischemia on either
exercise electrocardiography, 24-h Holter monitoring, or dynamic perfusion scintigraphy
(198). CAD in patients with type 1 diabetes is more diffuse, with a higher likelihood of
stenosis of all three major coronary arteries in the distal segments (199). The involvement
of distal segments renders the patients frequently unsuitable for bypass grafts. The
mortality rate of CAD events in patients with diabetes is also higher (200, 201).
Despite lipid variables and CAD events being extensively studied in the general
population and in patients with type 2 diabetes,  data on patients with type 1 diabetes are
surprisingly scarce. Which lipid variable is the best predictor of an incident CAD event
and how concomitant renal status affects this relationship are unknown.
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2.3 Lipoprotein metabolism
Lipoprotein particles transport non-water-soluble cholesterol and triglycerides in plasma
and consist of a hydrophilic surface monolayer of phospholipids, free cholesterol, and
apolipoproteins  (Apo)  and  a  central  core  of  hydrophobic  cholesterol  esters  and
triglycerides. They can be classified into five major classes according to their hydrated
density by ultracentrifugation: chylomicrons (density (d) <0.93 g/ml), very-low-density
lipoproteins (VLDL, d=0.93-1.006 g/ml), intermediate-density lipoproteins (IDL,
d=1.006–1.019 g/ml), low-density lipoproteins (LDL, d=1.019−1.063 mg/dl), and high-
density lipoproteins (HDL, d=1.063–1.21 mg/dl) (202).
The largest lipoprotein particles, chylomicrons, are responsible for the transport of dietary
triglycerides and cholesterol. They consist mainly of triglycerides (~85-90%), cholesterol
esters, phospholipids, and ApoB48. ApoB48 is intestinally produced and has 48% of the
molecular weight of ApoB100 (hereafter  referred  to  as  ApoB).  In  addition  to  ApoB48,
chylomicrons  also  contain  ApoA-I  and  acquire  ApoC-I,  -II,  -III,  and  ApoE  from  HDL
particles. The close interrelationship between the metabolic pathways for HDL particles
and triglyceride-rich lipoproteins is illustrated in Figure 4. In the circulation, the
triglycerides of the chylomicrons are hydrolyzed by the enzyme lipoprotein lipase (LPL)
into triglyceride-poorer particles, i.e. chylomicron remnants, which are taken up by the
liver.
VLDL particles are secreted by the liver and compromise endogenous triglycerides
(~55%) cholesterol (~25%), phospholipids (~18%), and ApoB, ApoA-II, ApoC-I, -II, -III
and ApoE (203). In the circulation, the triglycerides of the VLDL are also hydrolyzed by
LPL. During this process phospholipids, ApoC, and ApoE are transferred to HDL particles
and the VLDL particles are in turn transformed into IDL particles.
IDL particles contain ApoB and ApoE and lie between the VLDL and LDL particles in
their composition (203).  IDL particles can be taken up by the liver or they can be further
metabolized to LDL particles by the enzyme hepatic lipase (HL).
LDL particles consist of triglycerides (~6%), cholesterol (~55%), phospholipids (~20%),
and ApoB and are the main cholesterol-bearing lipoproteins in the plasma (203). Each
VLDL-IDL-LDL particle contains only one ApoB molecule, and therefore measuring
ApoB works as a marker of the number of these atherogenic lipoprotein particles in the
circulation (204).  As the plasma residence time of VLDL is ~2-6 h,  IDL ~1 h,  and LDL
~1.5-3 days (203, 205), about 90% of the circulating ApoB is found in the LDL particles
(206).
Lipoprotein(a) (Lp[a]) is an LDL-like lipoprotein, but in addition to ApoB, the
glycoprotein apolipoprotein(a) is also attached to the particle. Most people have very low
concentrations of Lp(a), but 2- to 4-fold higher concentrations are found in people of
African  origin  (207,  208).  Most  methods  to  measure  or  calculate  LDL  cholesterol
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concentrations do not distinguish between cholesterol derived from LDL or Lp(a), and
therefore, the reported LDL cholesterol is the net sum of cholesterol from both lipoprotein
particles.
HDL particles are secreted by the liver as small, lipid-poor lipoproteins, containing mostly
ApoA-I.  HDL  particles  are  in  a  constant  state  of  lipidation  and  delipidation  and
remodeling. ApoA-I constitutes about 70% of the protein content of HDL particles (209),
and each HDL particle contains one to five copies of ApoA-I. In addition, ApoA-II, -IV,
-V, ApoC-I, -II, -III, and ApoE may be present. All in all, HDL particles compromise over
100 proteins, which are considered to play an important role for the function of the HDL
particles (203). Nascent HDL particles receive cholesterol and phospholipids from
peripheral cells via the ATP-binding cassette A1 transporter. Within the HDL particles,
free cholesterol is esterified by the enzyme lecithin–cholesterol acyltransferase (LCAT),
leading to the formation of HDL3 particles. Thereafter, the phospholipid transfer protein
(PLTP)  enzyme  promotes  the  fusion  of  two  denser  HDL3 particles, leading to the
formation of one, more buoyant HDL2 particle (210). HDL2 particles are degraded by HL
and endothelial  lipase  to  HDL remnant  particles,  which  are  taken  up  by  the  liver  by  the
scavenger receptor (211).
Figure 4. Metabolic pathways for triglyceride-rich lipoprotein remnants and HDL
particles (modified from Chapman MJ et al., European Heart Journal 2011) (212).
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2.3.1 Actions of insulin on lipoprotein metabolism
By inhibiting the HL, insulin enhances the storage of triglycerides in the adipose tissue as
well as reduces the release of free fatty acids from the adipose tissue. Insulin has multiple
sites of action on lipid metabolism in the liver (Figure 5). It inhibits VLDL production in
the liver (213) and activates LPL in adipocytes (214), which promotes the catabolism of
triglyceride-rich lipoproteins (TRLs) (i.e. chylomicrons and VLDL particles). Moreover,
insulin decreases ApoB secretion by promoting ApoB degradation in the liver (215) and
also enhances the clearance of LDL by increasing the LDL B/E receptor activity (216).
Figure 5. VLDL secretion from the liver  is  regulated by insulin  through several  pathways  (green
arrows) and is increased in insulin-resistant states (red arrows) (modified from Choi SH and
Ginsberg HN, Trends in Endocrinology and Metabolism 2011) (217). Insulin suppresses FA
oxidation and de novo lipogenesis. It also suppresses MTP synthesis, which is a rate-limiting step
in hepatic VLDL production. Insulin can also directly affect apolipoprotein (Apo) B secretion by
targeting it for degradation, which inhibits VLDL secretion.  Expression of ApoC-III, an inhibitor of
lipoprotein lipase, is also suppressed by insulin. In insulin-resistant states, there is an increase in
the hepatic secretion of VLDL particles due to increased hepatic triglycerides from the enhanced
fatty acid flux to the liver, the excess availability of ApoB, and the increased de novo lipogenesis.
CM   =  chylomicron,  FFA  =  free  fatty  acids,  FA  =  fatty  acids,  DNL  = de novo lipogenesis, TG  =
triglycerides.
In patients with newly diagnosed type 1 diabetes with ketoacidosis and insulin deficiency,
a reduction of triglyceride-rich lipoprotein catabolism and a profound increase in TRLs,
mainly because of decreased LPL activity, can be observed (218, 219). HDL cholesterol
concentrations are also significantly decreased as a consequence of hypertriglyceridemia
(220).  In  contrast,  in  patients  with  type  1  diabetes  and  good  glycemic  control,  the
triglyceride concentration is usually normal or slightly decreased (218, 219, 221), due to
enhanced downregulation of VLDL production by increased plasma insulin concentrations
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as a consequence of subcutaneous insulin treatment (218, 222). Further, patients with type
1 diabetes display peripheral hyperinsulinemia, which increases the activity of LPL,
thereby lowering triglyceride concentrations (223). Plasma LDL cholesterol is normal or
even slightly decreased in patients with intensified insulin treatment as a consequence of
decreased VLDL production (223, 224). HDL cholesterol concentrations are normal or
slightly increased in patients with good glycemic control (219). The increase in HDL
cholesterol may be due to an increase in the LPL/HL ratio (due to increased LPL activity
and normal HL activity) (225), again as a consequence of peripheral hyperinsulinemia
caused by subcutaneous insulin treatment. Implantable insulin pumps with an
intraperitoneal insulin administration route mimic the physiological route of insulin and
should not lead to the peripheral hyperinsulinemia and hepatic hypoinsulinemia that the
subcutaneous route does. Studies evaluating the modification of the lipid profile after the
replacement of subcutaneous with intraperitoneal insulin treatment have, however, yielded
conflicting results. The HDL cholesterol concentrations have been shown to be decreased
(226) or unchanged (227-229), the triglycerides increased (226) or unchanged (227-229),
and the total cholesterol and ApoB unchanged (227, 228). Even though the subcutaneous
route of insulin administration occasionally seems to be associated with more favorable
quantitative changes in the lipid profile, it could, however, also be associated with
unfavorable qualitative changes, which could affect the function of the lipoprotein
particles.
2.3.2 Insulin resistance and lipoprotein metabolism
Insulin resistance is a typical feature of the metabolic syndrome and type 2 diabetes, but as
the prevalence of overweight and obesity is increasing in the society this feature is
becoming more common in patients with type 1 diabetes as well. Intensive glycemic
control can also cause overweight and insulin resistance, and these features are especially
common in those with a family history of type 2 diabetes. Moreover, renal disease is
associated with insulin resistance already at the early stages in patients both with and
without diabetes (230, 231). Insulin resistance is also considered to be a strong pathogenic
contributor to the progression of renal disease (232, 233).
Because LPL is insulin-dependent, its activity is commonly reduced in patients with
insulin resistance (234), resulting in longer residence times of the TRLs in the circulation.
The increased amounts of VLDL particles result, in turn, in an increased triglyceride
content in LDL particles through the action of the cholesteryl ester transfer protein
(CETP)  (235).  Triglyceride-rich  LDL  particles  are  good  substrates  for  HL,  which
hydrolyzes triglycerides, making the LDL particles smaller and denser (236). Small, dense
LDL (sdLDL) particles are frequently present in insulin-resistant states (237). In children
with  type  1  diabetes,  as  many  as  87%  had  a  phenotype  dominated  by  the  presence  of
sdLDL compared with only 11% in children without diabetes (238). SdLDL particles have
been found to be more atherogenic than the large, buoyant LDL particles for several
reasons: i) hepatic LDL receptors have a lower affinity for sdLDL particles, which leads to
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a prolonged plasma retention time of these particles (239), ii) sdLDL particles show
increased binding to intimal proteoglycans, which could favor penetration into the arterial
wall (240), iii) they are more effective in promoting lipid accumulation in macrophages,
which leads to an increased formation of foam cells  (241), iv) they are more likely to
undergo glycation (242), and v) they are more susceptible to oxidation (243, 244).
Oxidized LDL (oxLDL) particles are rapidly taken up by macrophages and promote the
formation of cytokines (e.g. tumor necrosis factor alpha [TNF-α] and IL-6) by
macrophages, accelerating the inflammatory atherosclerotic process (245).  In insulin-
resistant states, the LDL cholesterol concentrations are only slightly increased or similar to
those of controls, but the number of LDL particles is increased (246) (see Figure 6 for
illustration). Thus, as 90% of the circulating ApoB is found in LDL, ApoB is consequently
also increased when insulin resistance is present and can be seen as a surrogate marker for
the number of LDL particles (246).
Figure 6. Illustration of the same LDL cholesterol concentrations
with either normal or elevated apolipoprotein (Apo) B
concentrations.
The main reason for the decreased HDL cholesterol concentrations in insulin resistance
seems to be the increased transfer of triglycerides from the TRLs to the HDL particles and
the  reciprocal  transfer  of  cholesterol  from the  HDL particles  to  the  TRLs via  the  CETP
enzyme (235). Triglyceride-rich HDL particles are also good substrates for HL, making
them smaller and denser, and this increases the catabolism and clearance of HDL particles
from the plasma (247) .The reduced HDL concentrations in insulin-resistant states are
typically seen as reduced HDL2b subspecies and an increase in the smaller and denser
HDL3b and  HDL3c subspecies (248). Mechanisms affecting HDL particles in insulin
resistance are shown in Figure 7.
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Figure 7. Mechanisms affecting HDL cholesterol and apolipoprotein (Apo) A-I concentrations and
functionality in insulin-resistant states (modified from Drew BG et al., Nature Reviews
Endocrinology 2012) (249).
2.3.3 Apolipoproteins in diabetes
Insulin exerts multiple effects on the major apolipoproteins (ApoB, ApoA-I, ApoC-III,
and ApoE).  In patients with type 1 diabetes and fairly good glycemic control,  the ApoB
concentrations are within the normal range (224) and the ApoA-I concentrations are
slightly elevated or within the normal range (250). In normal physiology, insulin promotes
ApoB degradation in the hepatocyte and leads to decreased ApoB secretion from the liver
(215). In type 1 diabetic patients with ketoacidosis and total lack of insulin, the ApoB
concentrations are in the upper normal range, but decrease during insulin treatment with a
concordant and significant decrease in VLDL ApoB, but not in IDL or LDL ApoB (220).
In insulin-resistant states, the ApoB degradation is decreased, there is an increased
production of large VLDL1 particles, and the catabolic rate of ApoB-containing
lipoproteins, especially IDL and LDL, is reduced (215, 251). Interestingly, increased
ApoB concentrations can already be observed in children with type 1 diabetes as well as in
healthy children with diabetic parents compared with healthy children with non-diabetic
parents (252). The ApoA-I concentrations are near the normal range already before the
initiation of insulin treatment in type 1 diabetic patients with ketoacidosis; however, the
ratio of ApoA-I to cholesterol in the HDL particles falls during treatment (220). In insulin-
resistant states, the triglyceride loading of core HDL leads to rapid triglyceride lipolysis
and the formation of denser HDL particles, and the loss of HDL core triglycerides, in turn,
leads to the release of ApoA-I from HDL particles. ApoA-I then undergoes glomerular
filtration and the catabolic loss of ApoA-I is increased by 48% (251, 253). However,
ApoA-I production is increased by 25%, probably due to a compensatory mechanism, but
the net effect is still a reduction in ApoA-I concentrations.
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In insulin-resistant states, the inhibitory role of insulin in ApoC-III expression may be lost
and the high glucose levels may further stimulate ApoC-III expression (254). Increased
free fatty acid delivery to the liver also increases the ApoC-III secretion. ApoC-III inhibits
the LPL-mediated catabolism of VLDL and the uptake of VLDL by the liver and may also
increase VLDL secretion (203). The ApoE polymorphism influences total and LDL
cholesterol as well as ApoB concentrations, but the allele frequency of ApoE in patients
with type 1 diabetes does not differ from that of the general population in Finland (218).
Glycation is also likely to affect the function of apolipoproteins, and in patients with
hyperglycemia glycation of ApoA-I, ApoA-II, ApoB, ApoC-I, and ApoE has been
observed (255).
2.3.4 Secondary changes in lipid profile in nephrotic syndrome
Nephrotic syndrome is defined as proteinuria of >3.5 grams/24 h/1.73 m2 (256).  It  is
accompanied by hypoalbuminemia, edema, thrombophilia, increased risk of infections,
and dyslipidemia. The low plasma albumin concentrations, the oncotic pressure, and the
renal protein leakage are thought to play important roles in the development of lipid
abnormalities. Impaired catabolism and increased synthesis of ApoB-containing
lipoproteins and their remnants as well as an accumulation of oxLDL particles is observed
in patients with the nephrotic syndrome (257, 258). Lp(a) has also been found to be
elevated in patients with the nephrotic syndrome (259), but this can be reversed by
antiproteinuric treatment (260). The plasma concentrations of total HDL cholesterol are
often normal in patients with nephrotic syndrome, but the maturation of the HDL particles
is impaired and qualitative alterations can therefore be seen. Urinary loss of LCAT results
in  plasma  LCAT  deficiency  and  as  a  consequence  the  maturation  of  the  small,  dense
HDL3 particles  to  large,  buoyant  HDL2 particles is altered (261). This leads to high
concentrations of HDL3 and low concentrations of HDL2 particles and may also cause
disturbances in the reverse cholesterol transport system.
2.3.5 Possible mechanisms for lipid-induced renal injury
The mechanisms by which dyslipidemia could cause or induce renal injury remains
unclear, but similarities between atherosclerosis and glomerulosclerosis were recognized
already more than 20 years ago (262). Notably, genetic lipid disorders, such as deficiency
in LCAT, abnormalities in ApoE, and familial type III hyperlipoproteinemia, lead to renal
disease (263-265). Further, when guinea-pigs and rats are fed cholesterol-rich food, they
develop various forms of glomerular and other injuries (266, 267). On the other hand, lipid
abnormalities alone may be insufficient to cause renal injury since dyslipidemia in non-
diabetic human individuals is rarely associated with renal disease. Therefore, there is
likely a trigger that causes the initial renal injury, which is then aggregated by
dyslipidemia. Hyperglycemia, hypertension, or inflammation, often seen in patients with
diabetes, could serve as such a trigger (see also Figure 1).
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Lipoproteins enhance matrix expansion, mesangial cell proliferation, and mesangial
cytokine production (268-270). The increased cytokine production may recruit
macrophages, and similarly as observed in the arterial wall, infiltration of macrophages
and foam cells can be found in the glomeruli of patients with diabetic nephropathy (271).
Hyperglycemia causes mitochondrial overproduction of reactive oxygen species (ROS)
and synthesis of AGEs (272). Further, glycated VLDL and LDL particles are more
susceptible to oxidation (273), and AGE-modified LDL particles are cleared from the
plasma more slowly (274). As the kidney is a major site for AGE adduct clearance, it is
thought that AGE-modified lipoproteins may damage the glomeruli. Also, hyperlipidemia
on its own can promote inflammation and the generation of ROS by monocytes (275).
Both monocytes and mesangial cells may oxidize lipoproteins (275, 276), and oxLDL
particles may serve as chemoattractants for both T-lymphocytes and macrophages (277).
Scavenger receptors on the mesangial cells have higher affinity for oxLDL than for native
LDL, and stimulation by oxidized lipoproteins leads to mesangial cytokine production and
further recruitment of monocytes (274). Cytokine production by tubular epithelial cells is
stimulated by the presence of cytokines and high molecular proteins in the glomerular
filtrate. Further, oxLDL particles may increase apoptosis of mesangial cells, endothelial
cells, and podocytes (278-280). OxLDL can also cause vasoconstriction by increasing the
production of vasoactive substances and reducing the production of vasodilators (281).
Inflammatory  factors,  such  as  TNF-α,  ROS,  and  oxLDL,  may  cause  disruption  of  the
glycocalyx, which is vasoprotective and influences the glomerular permeability (282).
OxLDL,  hyperglycemia,  and  ROS  can  also  stimulate  the  production  and  activity  of  the
transforming growth factor (TGF)-β (274, 283). TGF-β activation leads to an increase in
the synthesis of extracellular matrix proteins and an impairment in extracellular matrix
degradation (284). Moreover, TGF-β stimulates nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase 2 (Nox2), and Nox4 expression in kidney fibroblasts,
activating the extracellular signal-regulated kinase ½ (ERK½) pathway. This results in
conversion of fibroblasts to a myofibroblast phenotype, which is associated with
interstitial fibrosis (285). Dyslipidemia may also cause alterations in the coagulation-
fibrinolysis system, a decreased renal blood flow, and endothelial cell damage (286).
2.4 Lipid-lowering treatment
Statins inhibit the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
enzyme, which plays a central role in hepatic cholesterol synthesis (287). Strong evidence
indicates that statins reduce CVD events in patients with diabetes, but almost all trials in
patients  with  diabetes  have  mainly  included  patients  with  type  2  diabetes.  The  trials
including the largest numbers of patients with diabetes are the Heart Protection Study
(HPS) (288), the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm
(ASCOT-LLA) (289), the Collaborative Atorvastatin Diabetes Study (CARDS) (290), and
the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial –
Lipid-Lowering Trial (ALLHAT-LLT) (291) including almost 15 000 patients with
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diabetes. The largest cohort of patients with type 1 diabetes is found in the HPS with 615
patients (288). In this particular trial, the magnitude of the reduction in CVD events was
similar  in  patients  with  type  1  and  type  2  diabetes,  although  the  reduction  was  not
statistically significant in the former group due to lower power.  In a meta-analysis of 14
trials including 18 686 patients with diabetes (1466 with type 1 diabetes), major vascular
events were reduced by 21% per 1 mmol/l reduction in LDL cholesterol during an average
follow-up of 4.3 years (292). The findings were independent of the baseline lipoprotein
concentrations, and similar benefits were seen irrespective of age, sex, type of diabetes, or
kidney status. Based on this meta-analysis, the number needed to treat (NNT) to prevent
one vascular event was as low as 9 for high-potency statins and 22 for low-potency statins.
Economic analyses of randomized statin trials, including the HPS, have shown that statin
treatment is cost-effective for a wide range of patients with diabetes (293).
The lipid-lowering mechanisms of the fibrates, i.e. peroxisome proliferation activator
receptor (PPAR)-α agonists, include activation of LPL and reduced production of ApoC-
III, leading to an increased clearance of VLDL and IDL particles (294). Rather
inconsistent results have been reported on the effect of fibrates on cardiovascular
outcomes. In a meta-analysis with 45 058 participants, a 13% relative risk (RR) reduction
was found for CAD events, but no benefits on stroke or all-cause mortality were seen. In
patients  with  type  2  diabetes,  the  results  regarding  the  overall  primary  end-points  have
been disappointing, but beneficial effects on CVD risk in patients with dyslipidemia
(defined as high triglycerides and low HDL cholesterol) at baseline have consistently been
reported (295-297). In the Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) Study, a significant 27% RR reduction was observed in patients with marked
dyslipidemia (triglycerides ≥2.3 mmol/l alone or with low HDL cholesterol
concentrations) at baseline treated with fenofibrate for 5 years compared with the non-
significant 11% RR reduction in the entire cohort (296).
2.4.1 Lipid-lowering treatment and progression of renal disease
Randomized clinical trials of lipid-lowering treatment with data on renal disease
progression are listed in Table 2.
Treatment with pravastatin or simvastatin has been associated with a modest reduction in
the rate of eGFR decline in non-diabetic cohorts with (or with a high risk of) coronary
heart disease (298, 299), and instead of the expected 5-year decline in eGFR, an
improvement of eGFR was seen in patients with atorvastatin treatment (300). In the HPS
trial, including patients with diabetes or occlusive arterial disease, simvastatin treatment
was associated with a smaller decrease in eGFR, and the effect was slightly larger among
patients with diabetes (288). In the CARDS Trial, comprising patients with type 2 diabetes
without prior CVD, atorvastatin treatment was associated with a modest improvement in
the annual change in eGFR (301), and in a substudy of the Treating to New Targets (TNT)
trial in patients with diabetes and CAD, 10 mg and 80 mg of atorvastatin increased eGFR
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in patients with or without moderate CKD, with a more significant increase in eGFR in
patients treated with the higher atorvastatin dose (302). In a meta-analysis of 39 704
patients, including both patients with and without diabetes, the eGFR decline was 1.22
ml/min/year slower with statin treatment; however, subgroup analyses showed no
significant differences in patients with diabetic nephropathy and the between-study
heterogeneity was considerable (303). In a recently published meta-analysis of 41 trials
with a total of 88 523 patients, statin treatment modestly reduced the rate of decline in
eGFR compared with placebo (standardized mean difference 0.15, p=0.0004) (304).
Twenty-one  of  these  trials  with  a  total  of  3933 patients  reported  data  on  urinary  protein
excretion, and a modest decrease in proteinuria with statin treatment was also seen. High-
and moderate-intensity statins significantly decreased the rate of reduction of eGFR,
whereas the difference between low-intensity statins and placebo was non-significant. The
authors concluded that the beneficial effect of statin treatment might be dosage-related and
duration-dependent. Statins reduced the decline in eGFR in patients with stage 1 to 3
CKD, but data were insufficient to analyze the effect of statins on patients with stage 4 to
5 CKD.
In the Justification for the Use of Statins in Prevention - an Intervention Trial Evaluating
Rosuvastatin  (JUPITER),  no  effect  on  eGFR  was  seen  after  12  months  of  rosuvastatin
treatment (305),  and a combination therapy of simvastatin and ezemitibe (an inhibitor of
cholesterol absorption in the gut) did not affect measures of kidney disease in pre-dialysis
patients  in  the  Study  of  Heart  and  Renal  Protection  (SHARP)  Trial  (306). Further,
fluvastatin treatment had no effect on the incidence of renal graft loss, doubling of serum
creatinine, or decline in GFR during a 5-year follow-up of 2102 renal transplant recipients
in the Assessment of Lescol in Renal Transplantation (ALERT) Study (307, 308).
However, in a meta-analysis including nine trials with atorvastatin treatment for 4194
patients with pre-dialysis CKD, a significant effect on eGFR was reported (309).
Fenofibrate treatment is associated with an initial increase in plasma creatinine, and hence,
a reduction of eGFR, but the increase has been reported to be reversible (310, 311), and in
a small study a reduction of GFR assessed by inulin clearance was not observed (312).
The results from the FIELD Study have been conflicting. In the FIELD Helsinki Substudy,
a decrease in eGFR and an increase in cystatin C with fenofibrate treatment were reported
(313). In another substudy of the FIELD cohort, fenofibrate initially decreased eGFR, but
after a washout period, eGFR had fallen less from baseline with fenofibrate than with
placebo treatment, 1.9 vs. 6.9 ml/min/1.73 m2 (p<0.001, after ~5 years), and a greater
benefit of eGFR preservation was seen with fenofibrate treatment in those with baseline
dyslipidemia (i.e. high triglycerides and low HDL cholesterol) (310). In the Diabetes
Atherosclerosis Intervention Study (DAIS), fenofibrate treatment reduced progression to
microalbuminuria, but the mean values of AER did not change (314). In the main results
of the FIELD Study, fenofibrate treatment modestly reduced the pooled end-point of
progression or regression of albuminuria status (295); however, in the Helsinki Substudy,
no beneficial effect on AER analyzed as a continuous variable could be seen (313). The
results of the FIELD Study may have been weakened by the use of other lipid-lowering
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treatment (mainly statins) in 36% of patients in the placebo group and in 19% of patients
in the fenofibrate group by the end of the study (295). However, in the ACCORD Study,
all patients received simvastatin treatment, but on top of this patients were randomized to
receive either fenofibrate or placebo (297). The combination of fenofibrate and
simvastatin modestly reduced progression to micro- or macroalbuminuria compared with
simvastatin treatment alone. In a meta-analysis with 14 385 patients with type 2 diabetes,
fenofibrate reduced the risk of albuminuria progression by 14% (315). Data on regression
of albuminuria status were available for 2152 patients, and the likelihood of regression
increased (RR 1.19) with fenofibrate treatment.
All in all, lipid-lowering treatment seems to have a modest beneficial effect on the decline
of eGFR and the development and progression of albuminuria. Most of the current
evidence on lipid-lowering treatment comes from patients with vascular disease already
present at baseline, and it is not known whether lipid-lowering intervention at an earlier
stage could provide benefits that may be lost at the later stages of diabetic nephropathy.
Further, the follow-up times of most randomized clinical trials are fairly short, and larger
benefits would likely be observed with longer treatment periods initiated earlier in the
course of the disease. For example, a loss-of-function mutation leading to a lifelong
reduction of LDL cholesterol of ~1.0 mmol/l was associated with ~88% reduction of CAD
(316), whereas LDL cholesterol lowering of a similar magnitude with statin treatment for
5 years reduces CAD events by ~35% (317). Animal studies have also suggested that the
combined effect of ACE inhibitors and statins might provide larger renal benefits than
either drug alone (318). In the future, the Adolescent type 1 Diabetes, cardio-renal
Intervention  Trial  (AdDIT)  will  show  the  results  of  the  combined  effect  of  an  ACE
inhibitor (quinapril) and atorvastatin on early surrogate measurements of diabetic
nephropathy and CVD (319) and hopefully provide us with new insight. Furthermore,
trials with hard renal end-points and direct GFR measurements (not only eGFR, which is
dependent on creatinine production and excretion) are also needed to clarify the situation.
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Table 2. Studies of lipid-lowering treatment and progression of renal disease.
Study
(ref)
Intervention Patients N, follow-up
time
Renal outcome Additional  information
ACCORD
(297)
Fenofibrate
160 mg/PBO
T2DM, high vascular
risk, all patients received
20-40 mg simvastatin
N=5518,
4.7 years
Incidence of micro 38.2% vs. 41.6%
(p=0.01). Incidence of macro 10.5%
vs. 12.3%  (p=0.04)
Reduced dose of fenofibrate if
eGFR <50 ml/min/1.73 m2
DAIS
(314)
Fenofibrate
200 mg/PBO
T2DM without
nephropathy
N=314,
3.3 years
Reduction of progression to micro
3.0% vs. 17.7% (p<0.001)
8% on fenofibrate and 18% on PBO
had higher AER at trial end
FIELD
(295)
Fenofibrate
200 mg/PBO
T2DM, majority without
overt nephropathy
N=9795,
5 years
2.6% less progression or more
regression of albuminuria (p=0.002)
Statistically significant if pooled with
regression of albuminuria
HPS
(288)
Simvastatin
40 mg/PBO
T1DM (3%), T2D(26%),
arterial disease without
DM (71%)
N=20 270,
(5963 with
DM) 4.6 years
Slower decrease in eGFR 5.9 vs. 6.7
ml/min/1.73 m2 (p=0·0003) during
follow-up
Effect on eGFR larger in patients
with diabetes
CARDS
(301)
Atorvastatin
10 mg/PBO
T2DM, no prior CVD,
34% impaired eGFR
N=2838,
3.9 years
Net improvement in eGFR 0.18
ml/min/1.73 m2/year
Net improvement 0.38
ml/min/1.73m2/year in those with
albuminuria
TNT
(302)
Atorvastatin
10 or 80 mg
T2DM, CAD N=1431,
4.8 years
Improvement in eGFR at the end of
follow-up in both treatment groups
0.5 vs. 2.6 ml/min/1.73 m2 (p=0.001)
ALERT
(307, 308)
Fluvastatin
40 mg/80
mg/PBO
Renal transplant
recipients, 13% with DM
N=2102,
6 years
No effect GFR measured directly in a subset
of 439 patients
SHARP
(306)
Simvastatin
20 mg and
Ezetimibe 10
mg/PBO
Dialysis or pre-dialysis
patients, 20% with DM
N=9270,
4.9 years
No effect Simvastatin 20 mg alone in 1054
patients for one year
PBO = placebo, T1DM = type 1 diabetes mellitus, T2DM = type 2 diabetes mellitus, micro = microalbuminuria, macro = macroalbuminuria
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2.4.2 Lipid-lowering treatment and progression of diabetic retinopathy
Data on the effect of statin treatment on diabetic retinopathy are lacking from large
randomized clinical trials, but because statin treatment is such an important part of the
prevention of CVD, it would today be considered unethical to have a placebo arm in a trial
including patients with increased CVD risk at baseline. Previously, the CARDS showed a
trend towards a reduced need of retinal laser treatment with atorvastatin treatment, but no
impact on the progression of diabetic retinopathy was seen (290). In contrast, large trials
investigating the effect of fibrate therapy on the development and progression of diabetic
retinopathy have been performed. In the FIELD Study, fenofibrate treatment significantly
reduced the need for the first laser treatment due to either PDR or macular edema (hazard
ratio [HR] 0.69). However, the need for laser treatment was not predicted by the baseline
plasma lipid concentrations (150). The NNT for prevention of laser treatment in patients
with pre-existing retinopathy was fairly low and clinically worthwhile (NNT=17), while
the results for primary prevention of diabetic retinopathy were not as convincing
(NNT=90).  In the FIELD Ophthalmology Substudy, a 2-step progression on the ETDRS
severity scale did not differ between the two groups overall, but among patients with pre-
existing retinopathy, fewer patients on fenofibrate had a 2-step progression than in the
placebo group. In the ACCORD Study, fenofibrate together with simvastatin treatment
reduced the rate of progression of diabetic retinopathy, defined as at least a 3-step
progression  on  the  ETDRS scale  or  the  development  of  PDR (HR 0.60)  compared  with
simvastatin treatment alone (167).
2.4.3 Lipid-lowering treatment and risk of development of type 2 diabetes
Cardiovascular risk factors and risk factors for type 2 diabetes are often present in the
same patients, therefore, many patients who are prescribed statin treatment already have
an increased risk for development of type 2 diabetes before initiation of statin treatment.
However, recent data have shown that statin treatment in itself is associated with a
modestly increased risk of type 2 diabetes. In a meta-analysis, statin treatment increased
the risk of diabetes development by 9% (320). In another meta-analysis, intensive-dose
treatment was associated with a 12% increased risk compared with moderate-dose statin
treatment, but intensive-dose treatment was also associated with fewer major CVD events
(OR 0.84) (31). Simvastatin, atorvastatin and rosuvastatin have all been associated with an
increased diabetes risk, but the results regarding pravastatin treatment have been
conflicting, and even protective effects have been reported (321). In an analysis from the
Jupiter Trial, rosuvastatin treatment was associated with a 39% reduction of the primary
CVD endpoint and a 28% increase in diabetes in patients with common risk factors for
diabetes, but in patients without risk factors for diabetes no increase in the risk of diabetes
development was seen (322). The increased diabetes risk is observed especially in older
patient groups. In a Finnish study, less weight loss during statin treatment was observed in
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elderly men (median age 73 years), hence, the possible positive protective effect of statin
treatment against frailty may paradoxically lead to a higher diabetes risk (323). Further, a
Mendelian randomization study showed that genetic variants in the HMG-CoA gene
associated with lower LDL cholesterol were also associated with an increased risk of type
2 diabetes and higher bodyweight (324). All in all, the risk of diabetes development with
statin treatment is fairly low and the cardiovascular benefits outweigh the diabetogenic
risk. The guidelines regarding cardiovascular prevention and statin treatment have
therefore not been altered. However, patients receiving statin treatment who have risk
factors for diabetes should be informed about the risk, receive support for lifestyle
changes, and regularly be monitored for hyperglycemia.
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3 AIMS OF THE STUDY
The main aims of this thesis were as follows:
I To examine the relationship between lipid variables, eGFR, and AER. A
further  aim  was  to  assess  the  effect  of  glycemic  control,  obesity,  and
hypertension on lipid profiles in patients without renal disease.
II To evaluate  the  impact  of  baseline  lipid  values  on  the  progression  of  renal
disease in patients with type 1 diabetes at all stages of albuminuria.
III To investigate the association between lipid variables and diabetic
retinopathy in patients with type 1 diabetes. Furthermore, interactions and
correlations between diabetic retinopathy, nephropathy, and lipid variables
were explored.
IV To assess the ability of lipid variables to predict incident CAD events in
patients with type 1 diabetes. Moreover, the effect of renal disease, sex, and
glycemic control on the ability of the lipid variables to predict CAD events
was explored.
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4 SUBJECTS AND STUDY DESIGN
4.1 The FinnDiane Study
These studies are part of the ongoing prospective Finnish Diabetic Nephropathy Study
(FinnDiane), a nationwide, multicenter study, initiated in 1997 that recruited its first
patients in January 1998. Prior to the FinnDiane Study, two pilot studies, GENREL and
NEFREL, that recruited families with diabetic nephropathy existed and the patients from
these studies were also included in the FinnDiane population. Follow-up data have been
collected since 2004. The aim of FinnDiane is to identify genetic, environmental, and
clinical risk factors for micro- and macrovascular complications in patients with type 1
diabetes, with a special emphasis on diabetic nephropathy. The main aims of FinnDiane
are to cover ~25% of all adult patients with type 1 diabetes in Finland and to answer the
question: why do one-third of patients with type 1 diabetes develop diabetic nephropathy?
Adult patients from 77 hospitals and primary healthcare centers in Finland have
consecutively been asked to participate in the study, and the response rate has been about
78% (325).  The study centers include all 5 university central hospitals, all 16 central
hospitals, 26 other hospitals, and 30 primary healthcare units in Finland (listed in the
Appendix).  The  geographic  distribution  of  the  FinnDiane  patients   (Figure 8)  closely
follows the distribution of the general population in
Finland, and the high response rate makes any major
significant biases unlikely. At the moment around
5000 patients with type 1 diabetes have been recruited,
which represents about 12.5% of all patients with type
1 diabetes in Finland.  In each study of this thesis, we
started with the inclusion of all patients with centrally
measured lipid profiles available from the database at
the  time  of  the  study  and  then  added  the  selection
criteria for each study, which are explained in more
detail below.
Figure 8. Distribution of the FinnDiane patients. Each dot indicates one FinnDiane patient. The
distribution is similar to the distribution of the general population in Finland.
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4.2 Collection of cross-sectional data
At baseline, patients underwent a thorough clinical investigation at a regular visit to their
attending physician. Data on diabetes duration, medication, diabetic microvascular
complications, smoking, and cardiovascular disease were registered based on medical
records and obtained by the patient’s attending physician using a standardized
questionnaire. The baseline data were obtained from patients who participated in the
FinnDiane Study between 1994 and 2008.
Figure 9.  Flow chart of patient selection in Study I.
Study  I:  At  the  time  of  the  study,  complete  lipid  profiles  were  obtained  from  3448
patients; the selection criteria are described in Figure 9. The clinical characteristics of the
patients grouped by albuminuria status can be seen in Table 3.
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Table 3. Clinical characteristics of subjects grouped by albuminuria status.
Data are means ± SD, median (IQR) or %. AER = albumin excretion rate, Micro = microalbuminuria, Macro =
macroalbuminuria.
Study III: Retinopathy status was determined in 1465 consecutively recruited patients with
complete lipid profiles. To avoid selection bias, these patients represent the first
consecutive patients participating in the FinnDiane Study. In addition, an independent data
set  of  1110  patients  without  ESRD  and  a  minimum  diabetes  duration  of  10  years  was
evaluated to replicate the interaction and correlation analyses.
4.3 Collection of follow-up data
Study II: At follow-up, all available medical files, including laboratory data, were
reviewed and any changes in renal status were verified. Prospective data were available
for 2412 patients. Patients with ESRD (n = 143) were excluded. Altogether, 2304 patients
participated in the study and were followed for 5.4 ± 2.0 years. Progression was defined as
a change from a lower to a higher level of albuminuria (normal AER to microalbuminuria,
or micro- to macroalbuminuria) or development of ESRD in patients with
macroalbuminuria at baseline.
Study IV: Complete baseline data, including centrally measured lipid profiles, were
available for 3872 patients. Follow-up data were obtained from the Finnish Hospital
Discharge Register (HILMO) based on hospital discharge records and the Causes of Death
Register through to 31.12.2010 and available for all patients. Patients with acute
myocardial infarction, coronary artery bypass graft surgery, or coronary angioplasty at
baseline were excluded (N=306). Further, patients with International Classification of
Normal AER Micro Macro
N 1959 453 515
Men (%) 48.2 58.5 57.9
Age (years) 35.5 ± 11.9 37.9 ± 11.7 40.9 ± 9.8
Age at onset (years) 16.2 ± 8.5 11.8 ± 7.9 11.7 ± 7.2
Diabetes duration (years) 19.3 ± 11.6 26.1 ± 10.7 29.2 ± 7.8
Systolic blood pressure (mmHg) 129 ± 15 135 ± 17 144 ± 19
Diastolic blood pressure (mmHg) 78 ± 9 80 ± 10 83 ± 10
Body mass index (kg/m2) 24.8 ± 3.3 25.6 ± 3.6 25.8 ± 4.0
HbA1C (%) 8.2 ± 1.4 8.8 ± 1.5 9.0 ± 1.5
Albumin excretion rate (mg/24h) 8 (5-13) 56 (26-107) 497 (166-1270)
Serum creatinine (µmol/l) 83 ± 16 90 ± 19 171 ± 125
Current smoking (%) 22.2 29.6 29.1
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Diseases (ICD)-10 diagnosis codes I20 and I22-25 (ICD-9: 411-414) in the Finnish
Hospital Discharge Register, those with reported coronary heart disease, or those taking
long-acting nitroglycerin medication at baseline were excluded from the patient group
without an event during the follow-up period (N=46). Hence, a total of 3520 patients were
included and followed for a median of 10.2 (8.6-12.0) years.
4.4 Ethical aspects
The FinnDiane Study protocol was approved by the Ethics Committee of Helsinki
University Central Hospital (decision number: 491/E5/2006) as well as by the local ethics
committees of each participating study center and is being conducted in accordance with
the Declaration of Helsinki. All patients gave their written informed consent before
participation in the study. All research files used for data analyses were coded with ID
numbers and personal information is known only to the FinnDiane researchers.
The FinnDiane Study is an observational study; hence, no interventions for patients are
carried out. The only potential nuisance to patients is the possible pain caused by
venapuncture when blood samples are drawn as well as the extra time spent during study
visits and in completing questionnaires.
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5 METHODS
5.1 FinnDiane Study protocol
5.1.1 Definition of type 1 diabetes
Type  1  diabetes  was  defined  as  onset  of  diabetes  before  the  age  of  35  years  and  with
permanent insulin treatment initiated within one year of diagnosis. Adult patients with
type 1 diabetes from 77 hospitals and primary healthcare centers all over Finland were
consecutively invited to participate.
5.1.2 Definition of diabetic nephropathy
Nephropathy status was determined based on the measurement of albumin excretion rate
(AER) in at least two of the three consecutive 24-h or overnight urine collections.
5.1.3 Assessment of renal function
Estimated glomerular filtration rate (eGFR) was calculated on the basis of a single serum
creatinine measurement using the Cockcroft–Gault formula adjusted for body surface area
(71) (Studies I and II), the Modification of Diet in Renal Disease (MDRD-4) equation (72)
(Studies II and III), or the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) formula (73) (Study IV).
The Cockcroft-Gault formula is calculated as:
              -the constant is 1.23 for men and 1.04 for women
The MDRD-4 equation is calculated as:
eGFR = ([140-age] x weight [kg] x constant) / creatinine
eGFR =32788 x creatinine -1.154 x age-0.203 x (0.724 if female)
Normal AER:
AER<20 μg/min
or <30 mg/24 h
Macroalbuminuria:
AER≥200 μg/min
or AER≥300
mg/24 h
Microalbuminuria:
20£AER<200 μg/min
or 30£AER<300
mg/24 h
ESRD:
Dialysis or
kidney
transplant
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The CKD-EPI formula is calculated as:
In Study I, patients were divided into three groups on the basis of the eGFR calculated
with the Cockcroft–Gault formula:
5.1.4 Definition of diabetic retinopathy
Fundus photographs taken by the participating study centers were scanned and stored in a
digital archive; these were available for 1128 (77%) of 1465 patients. Ophthalmic records
with information about fundus examinations were also obtained. The clinical fundus
examination is important because it has good specificity (326) and the combination of
fundus photographs and a clinical examination provide both good sensitivity and
specificity for detection of severe diabetic retinopathy. The data were analyzed by a
specialist in ophthalmology (Kustaa Hietala) who was unaware of the demographic data
and the presence of other complications. The ETDRS scale was used to grade the severity
of diabetic retinopathy, with 10 defined as no diabetic retinopathy, 20-35 as mild non-
proliferative diabetic retinopathy (NPDR), 43-53 as moderate to severe NPDR, and 61 and
over as proliferative diabetic retinopathy (PDR) (327).  The eye with the more severe
diabetic retinopathy was used to determine the retinopathy stage for a patient. For patients
without available fundus photographs the verbal descriptions of clinical fundus
examinations by ophthalmologists were transformed to approximate numerical values on
the ETDRS scale. In an independent cohort in Study III, severe diabetic retinopathy was
defined as history of laser photocoagulation. The underlying cause for laser treatment was
PDR in the majority (>80%) of patients, and the rest of the patients received laser
photocoagulation mainly due to macular edema or severe non-proliferative retinopathy
(161).
ETDRS severity scale:
a) Female S-Creatinine ≤ 61.9 µmol/l: eGFR = 144 × (creatinine / 61.9)-0.329 × (0.993)age
b) Female S-Creatinine > 61.9 µmol/l: eGFR = 144 × (creatinine / 61.9)-1.209 × (0.993)age
c) Male S-Creatinine ≤ 79.6 µmol/l: eGFR = 141 × (creatinine / 79.6)-0.411 × (0.993)age
d) Male S-Creatinine > 79.6 µmol/l: eGFR = 141 × (creatinine / 79.6)-1.209 × (0.993)age
Normal renal
function:
>90 ml/min/1.73 m2
Mildly impaired
renal function:
60-90 ml/min/1.73 m2
Impaired renal
function:
<60 ml/min/1.73 m2
No retinopathy:
Level 10
Mild NPDR:
Level 20-35
Moderate to severe
NPDR: Level 43-53
PDR:
Level ≥ 61
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5.1.5 Definition of cardiovascular disease (CVD)
A CVD event was defined as a history of myocardial infarction, stroke (cerebral infarction
or intracerebral hemorrhage), or amputation. In Study I, coronary heart disease (CHD) was
defined as myocardial infarction, coronary revascularization, or regular use of long-acting
nitroglycerin.
5.1.6 Definition of coronary artery disease (CAD)
In Study IV, an incident CAD event was defined as myocardial infarction given as ICD-10
code I21 (ICD-9: 410), coronary artery bypass graft surgery, or coronary angioplasty.
Author Nina Tolonen from the FinnDiane Study group verified the Finnish Hospital
Discharge  Register  (HILMO)  data  by  reviewing  the  hospital  records  of  28%  of  the
patients.  In  this  sample,  no  typing  errors  were  found,  and  only  four  borderline  cases  of
acute myocardial infarction were identified. Otherwise, all cases were in accordance with
the universal definition of myocardial infarction (328) or had undergone either coronary
artery bypass graft surgery or coronary angioplasty. Fatal CAD events were identified
from a search of the Finnish Causes of Death Register and established when the immediate
or underlying cause of death was from CAD, i.e. given as ICD-10: I20-25 (ICD-9: 410-
414). Death certificates were also obtained to verify the register data.
5.1.7 Anthropometric measurements
Weight and height were recorded with 0.1 kg and 1 cm accuracy, respectively. Waist
circumference was measured halfway between the lowest rib and the iliac crest. Hip
circumference was measured at the major trochanters of the femurs. Waist-to-hip ratio
(WHR) was calculated by dividing the waist circumference by the hip circumference.
Body mass index (BMI) was calculated as weight/height2 (kg/m2).
In Study I, patients were divided into three groups based on their BMI:
5.1.8 Assessment of blood pressure
Blood pressure was measured twice from the brachial artery at 2-min intervals in the
sitting position after a 10-min rest. A manual sphygmomanometer or an automated blood
pressure measurement device was used.  The mean value of at least two measurements
was used in the analyses.
Normal BMI:
< 25 kg/m2
Overweight:
25–30 kg/m2
Obesity:
> 30 kg/m2
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In Study I, hypertension was defined as the use of antihypertensive medication or
systolic/diastolic blood pressure higher than 130/80 mmHg (116).
5.1.9 Definition of smoking
Current smoking was defined as smoking at least one cigarette per day at the time of data
collection. History of smoking was defined as smoking at least one cigarette per day for a
minimum of 3 months but ceasing to smoke before data collection.
5.2 Laboratory measurements and assays
5.2.1 Lipids and lipoproteins
All serum lipid and lipoprotein concentrations were measured from blood samples in
Professor Marja-Riitta Taskinen’s research laboratory at Helsinki University Central
Hospital, Division of Cardiology, Helsinki, Finland. Total cholesterol and triglycerides
were determined enzymatically using a Cobas Mira analyzer (Hoffman-La Roche, Basel,
Switzerland) with commercially available kits (Hoffman-La Roche until November 2001
and ABX Diagnostics, Montpellier, France until January 2006). Thereafter, an enzymatic
determination by Konelab 60i analyzer (Thermo Fisher Scientific, Waltham, MA, USA)
and a kit from the same manufacturer were used. Total HDL and HDL3 cholesterol were
determined enzymatically using a HTS 7000 Plus Bio Assay Reader (Perkin Elmer,
Waltham, MA, USA) with a commercial kit from Roche Diagnostic Hitachi (Hitachi,
Tokyo, Japan). HDL2 cholesterol was calculated by subtracting HDL3 cholesterol from
total HDL cholesterol. LDL cholesterol was calculated with the Friedewald formula if
triglycerides were below 4.0 mmol/l (329). Serum ApoB concentrations were determined
using a Cobas Mira analyzer by immunoprecipitation with a commercial kit (Orion
Diagnostica, Espoo, Finland) until January 2006. Thereafter, an immunoprecipitation
method with a Konelab 60i analyzer and a kit from the same manufacturer (Thermo Fisher
Scientific) were used. Serum ApoA-I concentrations were determined with a Cobas Mira
analyzer by immunoprecipitation with commercial kits (Boehringer-Mannheim until
January 2002 and Wako Chemicals GmbH, Neuss, Germany until January 2006), and
thereafter, with a Konelab 60i analyzer by immunoprecipitation (Thermo Fisher
Scientific). Serum ApoA-II concentrations were determined with a Cobas Mira analyzer
by immunoprecipitation with a commercial kit (Boehringer-Mannheim until August
2001), and thereafter, a polyclonal antibody produced in sheep against human ApoA-II
was used.
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In Study I, cut-off values based on the recommendation of the American Diabetes
Association (116) were as follows: LDL cholesterol ≤2.6 mmol/l, triglycerides
≤1.7 mmol/l, and HDL cholesterol ≥1.0 mmol/l for men and ≥1.3 mmol/l for women.
5.2.2 HbA1c
Glycosylated hemoglobin A1c (HbA1c) was determined locally at each center by
standardized assays. In Study I, patients were divided into three groups with regard to
glycemic control:
5.2.3 Assessment of insulin sensitivity
To estimate insulin sensitivity, estimated glucose disposal rate (eGDR) was calculated
with an equation developed by Williams et al. (124) based on clinical risk factors and
validated with euglycemic-hyperinsulinemic clamp measurements in a subset of the
Pittsburgh EDC Study population. An equation modified for use with HbA1c instead of
HbA1 was used in this study.
      Hypertension is defined as antihypertensive treatment and/or blood pressure ≥140/90 mmHg
       (yes = 1, no = 0).
5.2.4 Creatinine
Serum creatinine was measured with a kinetic Jaffé reaction using a Hitachi 911 E
analyzer (Boehringer Mannheim, Mannheim, Germany) until January 2002. Thereafter, a
photometric, enzymatic (isotope dilution mass spectrometry = IDMS) method using a
Hitachi 917 or Modular analyzer (Boehringer Mannheim/Roche Diagnostics, Basel,
Switzerland) was applied. The correlation coefficient between the two methods is 0.988.
To enable use of the data derived from both methods, the following conversion formula
was applied:
eGDR = 24.4 − 12.97 x WHR − 3.39 x hypertension − 0.60 x HbA1c
S-Creatinine (IDMS) = (0.953 x S-Creatinine Jaffé) - 7.261
Good glycemic
control:
HbA1c < 7.5%
Intermediate glycemic
control:
HbA1c 7.5-9%
Poor glycemic
control:
HbA1c > 9%
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5.2.5 Urinary albumin excretion rate (AER)
In addition to the urine collections used for the classification of renal status, AER was also
measured centrally from 24-h urine collections. It was measured by radioimmunoassay
using a LKB Wallac RiaGamma counter (Pharmacia, Uppsala, Sweden) until November
2002. Thereafter, an immunoturbidimetric method was used with a Hitachi 911 analyzer
(Roche Diagnostics, Hoffman-La Roche, Basel, Switzerland). This measurement was
included in the multivariate analyses.
5.3 Lipid-lowering medication
Lipid-lowering medication was defined as the use of statins, fibrates, and/or ezetimibe;
however, only a few patients were on fibrate or ezetimibe therapy. The active substance
and doses of patients’ lipid-lowering medication were registered. In Study I, patients with
lipid-lowering medication were excluded from the analyses. In the other studies, parts of
the analyses were performed correcting for or excluding patients with lipid-lowering
medication.
5.4 Statistical analyses
Data for normally distributed and continuous variables are presented as mean ± standard
deviation (SD) and data for non-normally distributed variables as median with
interquartile range (IQR). Differences between groups were analyzed with Student´s t-test
or ANOVA for normally distributed variables between two or three groups, respectively.
Differences between non-normally distributed variables for two groups were analyzed
with the Mann-Whitney U-test and for three groups with the Kruskal-Wallis test.
Categorical variables were analyzed using Pearson’s c2 test. Values of p for lipid variables
for comparison between groups were adjusted for age, sex, and BMI. Pearson’s correlation
coefficients were used to calculate correlations between normally distributed values, and
Spearman’s rank correlation coefficients were used for non-normally distributed values.
Non-normally distributed values were logarithmically transformed before inclusion in the
multivariate models.
In Study I, multiple linear regression analyses were performed with either eGFR or AER
as the dependent variable.
5.4.1 Study II
Cox proportional hazards model was used to investigate the relationship between possible
predictors of progression of diabetic nephropathy. Results are presented as hazard ratios
(HRs) with 95% confidence intervals (CIs). A standard model, including conventional risk
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factors, i.e. diabetes duration, HbA1c, SBP, sex, BMI, and current smoking, was used for
the analyses. Receiver-operating characteristic (ROC) curves were performed to identify
possible thresholds of triglycerides for the prediction of renal disease. The shortest
distance on the ROC curve corresponding to the maximum sum of sensitivity and
specificity was used in the determination of cut-off points.
5.4.2 Study III
PDR or mild NPDR was the dependent variable in multiple logistic regression analyses.
To determine whether the lipid variables have a different effect on AER depending on
retinopathy status, interaction terms between retinopathy status (no retinopathy, mild
NPDR, moderate to severe NPDR, PDR) and lipid variables were explored with linear
regression models where the natural logarithm of (ln)AER was the dependent variable.
The relationship between lipid variables and retinopathy status was further analyzed with
least square estimates for ln AER, which were calculated after stratification of the data by
quartiles of triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, and
retinopathy status groups. Back-transformation resulted in geometric means adjusted for
diabetes duration, SBP, and HbA1c (Figure  1  in  Study  III).  Patients  with  ESRD  and  a
diabetes duration of less than 10 years were excluded from correlation and interaction
analyses and from Figure 1. In the additional correlation and interaction analyses in an
independent data set, retinal laser treatment (yes, no) was used to stratify the cohort.
Patients with ESRD and diabetes duration of less than 10 years were also excluded from
these analyses.
5.4.3 Study IV
To analyze the associations between risk factors and incident CAD events, univariate and
multivariate Cox regression models were used. Variables included in the multivariate
models were all univariately associated with CAD and every variable reduced the Akaike
information criteria (AIC), except for sex, but since it is a well-established CAD risk
factor, it was included in the models. The multivariate models included diabetes duration,
HbA1c, SBP, sex, WHR, eGFR, retinal laser treatment, AER, history of smoking, and one
of the lipid variables. Because of collinearity, only one of the lipid variables was entered
into the models at  a time. Results are presented as HRs per SD increase,  with 95% CIs.
The standardized score for WHR was calculated separately for men and women. Fine and
Gray regression analyses were also performed to take into account the competing event of
non-CAD death (330).  After the Fine and Gray competing risks analyses were performed,
figures of the cumulative incidence for CAD in normoalbuminuric or macroalbuminuric
patients divided by the median of lipid variables were drawn. To compare the ability of the
lipid variables to predict an incident CAD event, we calculated the area under the ROC
curves (AUC). Further, likelihood ratio (LR) χ2 statistics from the Cox models were
calculated, a higher value indicating a better global fit. Net reclassification improvement
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(NRI) is the percentage reclassified after the inclusion of the variable of interest in the
above-mentioned multivariate model, distinguishing between movements in the correct
direction, i.e. the proportion of subjects being reclassified to a higher risk category
amongst CAD cases or a lower risk category amongst controls (331). The 5%, 10%, and
20% cut-off points have been proposed as relevant in clinical-decision making for CAD
prevention (332, 333) and were therefore chosen as the NRI cut-off points.
In the multivariate models in Studies I and II, a p-value of < 0.05 was considered
significant. Otherwise, a more stringent level of significance (p<0.01) was chosen in order
to correct for multiple testing. Statistical analyses were performed using SPSS 12.0.1,
15.0,  PASW  Statistics  18  for  Windows  (SPSS  Inc.,  Chicago,  IL,  USA),  Statistical
Analysis System version 9.2 (SAS Institute, Cary, NC, USA), STATA Data Analysis and
Statistical Software (StataCorp LP, College Station, TX, USA), and MedCalc (MedCalc
Software bvba, Ostend, Belgium).
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6 RESULTS
6.1 Associations between lipid profiles, AER, and eGFR (Study I)
Patients with impaired renal function had higher total cholesterol, LDL cholesterol,
triglycerides, and ApoB and lower HDL cholesterol than patients with normal or only
mildly impaired renal function (Table 4). The lipid profiles of patients with mildly
impaired renal function were similar to those with normal renal function.
When patients were divided by their albuminuria status, lipid abnormalities could be seen
already at the microalbuminuric stage for total cholesterol, triglycerides, and ApoB
(p<0.001 for all). In macroalbuminuric patients, the lipid disturbances were further altered
with  higher  total  cholesterol,  LDL  cholesterol,  triglycerides,  and  ApoB  as  well  as  with
lower HDL, HDL2,  and  HDL3 cholesterol than in both normo- and microalbuminuric
patients (p<0.001 for all).
Table 4. Lipid profile stratified by estimated glomerular filtration rate (eGFR).
eGFR >90 eGFR 60-90 eGFR <60
N 1505 857 228
Total cholesterol (mmol/l) 4.80 ± 0.95 5.04 ± 0.84 5.37 ± 1.10‡*
Non-HDL cholesterol (mmol/l) 3.51 ± 0.96 3.64 ± 0.89 4.12 ± 1.04‡*
LDL cholesterol (mmol/l) 2.98 ± 0.86 3.14 ± 0.80 3.40 ± 0.92‡*
Triglycerides (mmol/l) 1.00 (0.76-1.41) 0.95 (0.74-1.28) 1.38 (1.04-2.10)‡*
Apolipoprotein B (g/l) 0.87 ± 0.22 0.88 ± 0.21† 0.99 ± 0.25‡*
HDL cholesterol (mmol/l) 1.27 ± 0.34 1.40 ± 0.38 1.19 ± 0.39‡*
HDL2 cholesterol (mmol/l) 0.50 ± 0.23 0.61 ± 0.27 0.49 ± 0.26‡*
HDL3 cholesterol (mmol/l) 0.77 ± 0.18 0.79 ± 0.21 0.71 ± 0.20‡*
Apolipoprotein A-I (g/l) 1.36 ± 0.21 1.44 ± 0.22† 1.37 ± 0.23*
Data are means ± SD or median (IQR). †p<0.01, ‡p<0.001 vs. eGFR >90; *p<0.001 vs. eGFR 60–90. Data are
adjusted for age, body mass index, and sex.
Factors associated with eGFR and AER in multiple linear regression models
To study factors associated with eGFR, multiple linear regression analysis was performed.
Age, BMI, ApoB, and SBP were independently associated with eGFR (R2=0.28) (Table
5). When ApoB was replaced with triglycerides and LDL cholesterol, triglycerides were
also independently associated with eGFR (R2=0.28). When AER was added to the model
with ApoB, systolic blood pressure and ApoB were no longer independently associated,
but HDL cholesterol emerged as a new independently associated factor together with age,
BMI, and AER (R2=0.36).
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  Table 5. Factors associated with eGFR in a multiple linear regression analysis.
B SE β p-value
Age (years) −1.17 0.05 −0.45 <0.001
Systolic blood pressure (mmHg) −0.13 0.03 −0.08 <0.001
Body mass index (kg/m2) 2.18 0.15 0.26 <0.001
Apolipoprotein B (g/l) −10.39 2.34 −0.08 <0.001
R2=0.28. Patients with lipid-lowering treatment were excluded. The model also included HDL cholesterol.
eGFR= estimated glomerular filtration rate, B = unstandardized regression coefficient, SE = standard error
of B, β = standardized regression coefficient.
SBP, HbA1c, diabetes duration, ApoB, and HDL cholesterol were independently
associated with AER (R2=0.23) (Table 6). When ApoB was replaced with triglycerides
and LDL cholesterol, they were also independently associated with AER (R2=0.23). When
eGFR  was  added  to  the  model  with  ApoB,  it  was  also  an  independent  factor  for  AER
together with all of the other variables in the model (R2=0.27).
 Table 6. Factors associated with ln AER in multiple linear regression analysis.
B SE β p-value
Diabetes duration (years) 0.02 0.003 0.16 <0.001
Systolic blood pressure (mmHg) 0.02 0.002 0.21 <0.001
HbA1c (%) 0.23 0.02 0.20 <0.001
HDL cholesterol (mmol/l) -0.39 0.09 -0.09 <0.001
Apolipoprotein B (g/l) 1.29 0.16 0.17 <0.001
R2=0.23. Patients with lipid-lowering treatment were excluded. Ln AER= natural logarithm of albumin
excretion rate, B = unstandardized regression coefficient, SE = standard error of B, β = standardized
regression coefficient.
The relationship between eGFR and AER can be seen in Figures 10A and 10B.
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B
Figure 10. A) Frequency of normal (eGFR >90), mildly impaired (eGFR 60-90), or impaired (eGFR
<60) renal function when patients are stratified by albuminuria status. B) Frequency of normal
albumin excretion rate (normo), microalbuminuria (micro), or macroalbuminuria (macro) when
patients are stratified by renal function. eGFR= estimated glomerular filtration rate.
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Prevalence of patients achieving the targets for lipid variables
During the time of the data collection, 1994-2004, two targets for LDL cholesterol were in
use.  In  patients  without  manifest  renal  disease  who  had  good  glycemic  control,  normal
blood  pressure,  or  normal  body  weight,  only  51%  achieved  the  criteria  for  an  LDL
cholesterol target of ≤3.0 mmol/l and merely 41% the more stringent criteria of ≤2.6
mmol/l. In patients with renal disease, the treatment targets were achieved by even fewer
patients (Figure 11).
Figure 11. Prevalence of patients stratified by their albuminuria status reaching recommended
targets of LDL cholesterol (≤3.0 mmol/l) HDL cholesterol (≥1.0 mmol/l for men, ≥1.3 mmol/l for
women),  and  triglycerides  (≤1.7  mmol/l).  Normo  =  normal  albumin  excretion  rate,  micro  =
microalbuminuria, macro = macroalbuminuria, -C= cholesterol, TG= triglycerides.
6.2 Prediction of progression of renal disease by lipid profiles
(Study II)
During a follow-up of 5.4 ± 2.0 years, 100 patients developed microalbuminuria, 50
progressed from micro- to macroalbuminuria, and 92 progressed from macroalbuminuria
to ESRD. Hence, 242 (10.5%) of 2304 patients progressed to a higher level of albuminuria
or developed ESRD.
Patients who developed microalbuminuria or progressed from micro- to macroalbuminuria
had higher total cholesterol, non-HDL cholesterol, triglycerides, ApoB, and
triglyceride/HDL cholesterol ratio (p<0.001 for all)  at  baseline than patients who did not
progress.
Progressors from macroalbuminuria to ESRD had higher total cholesterol, LDL
cholesterol, non-HDL cholesterol, triglycerides, ApoB, ApoB/ApoA-I, and
triglyceride/HDL cholesterol ratio (p<0.001 for all), as well as lower HDL, HDL2,
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HDL2/HDL3 cholesterol ratio and ApoA-II concentrations (p<0.01 for all) than patients
who did not progress.
Lipid variables as independent predictors for progression of renal disease
In a Cox regression analysis, HbA1c, male sex, and triglycerides were independent
predictors of development of microalbuminuria and progression to macroalbuminuria.
When triglycerides were replaced with the other lipid variables one at a time, ApoB was
also an independent predictor of progression to both micro- and macroalbuminuria. When
AER was added to the original models, triglycerides were no longer an independent
predictor of progression to micro- or macroalbuminuria. However, when the two groups
were pooled; HbA1c, male sex, triglycerides, and AER were all independent predictors of
progression of renal disease.
High SBP, low BMI, and high triglycerides were predictive of progression from
macroalbuminuria to ESRD. Total cholesterol, non-HDL cholesterol and triglyceride/HDL
cholesterol ratio were also strong predictors of progression to ESRD (p<0.001). However,
when baseline eGFR was included in the models, only total cholesterol predicted
progression to ESRD together with HbA1c and eGFR.
When ROC curves were created no thresholds for triglycerides and progression of renal
disease were identified. To determine at which triglyceride concentration the risk for renal
disease progression increases, we also prepared predictive probability plots for
progression from normo- to microalbuminuria and from macroalbuminuria to ESRD
(Figure 12). The risk of progression increased linearly until a triglyceride concentration of
4 mmol/l was reached and no clinically relevant thresholds for triglycerides were seen.
 A
Figure 12A. Predicted probability plots for triglyceride concentrations
and progression from normal AER to microalbuminuria.
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B
Figure 12B. Predicted probability plots for triglyceride concentrations
and progression from macroalbuminuria to end-stage renal disease.
6.3 Associations between lipid variables, diabetic retinopathy,
and nephropathy (Study III)
Of 1465 patients, 381 had no signs of retinopathy, 405 had mild NPDR, 186 had moderate
to  severe  NPDR,  and  493  had  PDR.  Total  cholesterol,  non-HDL  cholesterol,  LDL
cholesterol, triglycerides, and ApoB were higher in patients with PDR and NPDR than in
patients without retinopathy (p<0.001 for all). HDL, HDL2,  and  HDL3 cholesterol were
also lower in patients with PDR than in patients without retinopathy or with NPDR in both
men and women (p<0.001 for all).
Diabetes duration and ln AER were positively associated, whereas eGFR and HDL
cholesterol (odds ratio [OR] 0.45 [95% CI 0.27-0.74] p=0.002, R2=0.48) were negatively
associated with PDR in logistic regression analysis. When HDL cholesterol was replaced
with other lipid variables one at a time, HDL2 cholesterol (OR 0.29 [95% CI 0.14-0.60]
p=0.001, R2=0.48) was also inversely associated with PDR. Diabetes duration, HbA1c, ln
AER, and ln triglycerides (OR 1.86 [95% CI 1.18-2.93] p=0.008, R2=0.44) were positively
associated and eGFR was negatively associated with mild NPDR. Patients with PDR or
moderate to severe NPDR were excluded from these analyses. When triglycerides were
replaced with the other lipid variables, ln triglyceride/HDL cholesterol ratio (OR 1.62
[95% CI 1.14-2.31] p=0.008, R2=0.44) was also positively associated with mild NPDR.
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When  patients  without  any  signs  of  renal  disease  (i.e.  normal  AER  or  eGFR
>60ml/min/1.73 m2) were analyzed separately, total cholesterol/HDL cholesterol ratio
differed significantly between the retinopathy status groups (p=0.007). Trends towards
differences in total cholesterol, non-HDL, HDL and HDL3 cholesterol and
triglyceride/HDL cholesterol ratio could also be seen (p<0.05).
Significant interactions between retinopathy status and triglycerides, non-HDL
cholesterol, ApoB, total cholesterol/HDL cholesterol ratio, and triglyceride/HDL
cholesterol ratio (p<0.001 for all) as well as total cholesterol (p=0.006) were found when
interaction terms between retinopathy status (no retinopathy, mild NPDR, moderate to
severe NPDR, PDR) and lipid variables were calculated in linear regression models with
ln AER as the dependent variable. Further, no significant correlations between the lipid
variables and AER were seen in patients without diabetic retinopathy, whereas the
correlations between AER and most of the lipid variables were strong in patients with
moderate to severe NPDR or PDR (Table 7).
Table 7. Spearman correlations between AER and lipid variables according to retinopathy status.
Patients with duration of diabetes less than 10 years and patients with end-stage renal disease were
excluded. AER= albumin excretion rate, NPDR = non-proliferative diabetic retinopathy, PDR = proliferative
diabetic retinopathy, Chol = cholesterol, NS = non-significant.
No
retinopathy
Mild NPDR Moderate to
severe NPDR
PDR
N (men/women) 141 (64/77) 320 (137/183) 144 (97/47) 318 (160/158)
Total cholesterol NS NS 0.20 (p=0.02) 0.21 (p<0.001)
Non-HDL cholesterol NS NS 0.27 (p=0.001) 0.24 (p<0.001)
LDL cholesterol NS NS 0.17 (p=0.04) 0.14 (p=0.02)
Triglycerides NS 0.18 (p=0.001) 0.35 (p<0.001) 0.36 (p<0.001)
Apolipoprotein B NS 0.16 (p=0.004) 0.36 (p<0.001) 0.25 (p<0.001)
HDL cholesterol NS NS -0.21 (p=0.01) -0.17 (p=0.002)
Apolipoprotein A-I NS NS NS NS
Total chol/HDL chol NS NS 0.29 (p<0.001) 0.26 (p<0.001)
Triglyceride/HDL chol NS 0.14 (p=0.01) 0.33 (p<0.001) 0.34 (p<0.001)
Apolipoprotein B/A-I NS NS 0.29 (p<0.001) 0.18 (p=0.001)
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6.4 Ability of lipid variables to predict incident CAD events
(Study IV)
Of 3520 patients, 310 (9%) suffered an incident CAD event during a median of 10.2 (8.6-
12.0) years of follow-up. In general, patients who had an incident CAD event were older,
had a longer duration of diabetes, higher SBP, WHR, and AER as well as lower eGDR
and eGFR. Of the lipid variables, total cholesterol, non-HDL cholesterol, LDL cholesterol,
triglycerides,  and  ApoB  were  higher  and  HDL  cholesterol  was  lower  in  patients  with  a
CAD event than in those without (Table 8).
Table 8. Lipid profile stratified by an incident coronary artery disease (CAD) event.
Data are means ± SD or median (IQR). †p<0.01, ‡p<0.001. P-values are adjusted for age, body mass index,
and sex (if not already stratified by sex). * Apolipoprotein A-I concentrations in men were 1.27 and 1.33 g/l
in no CAD and CAD event groups, respectively, when corrected for age and body mass index, and this
difference was significant.
To take into account the competing event of non-CAD death, we performed Fine and Gray
regression analysis (Table 9) in addition to the Cox regression analysis. Duration of
diabetes, eGFR, ApoB, SBP, and laser treatment were all independent predictors of CAD
in both analyses. In the entire cohort, ApoB, triglycerides, non-HDL cholesterol,
ApoB/ApoA-I ratio, and triglyceride/HDL cholesterol ratio were the strongest lipid
predictors of an incident CAD event.
No CAD event CAD event
N 3,037 310
Total cholesterol (mmol/l) 4.86 ± 0.92 5.42 ± 1.20‡
Non-HDL cholesterol  (mmol/l) 3.51 ± 0.96 4.20 ± 1.23‡
LDL cholesterol  (mmol/l) 2.97 ± 0.83 3.45 ± 1.00‡
Triglycerides (mmol/l) 0.98 (0.74-1.39) 1.30 (0.97-1.89)‡
Apolipoprotein B (g/l) 0.86 ± 0.22 1.00 ± 0.25‡
HDL cholesterol (mmol/l):  Men 1.24 ± 0.34 1.14 ± 0.34‡
                                     Women 1.46 ± 0.39 1.33 ± 0.41‡
HDL2 cholesterol (mmol/l): Men 0.47 ± 0.24 0.44 ± 0.23‡
                                     Women 0.64 ± 0.28 0.57 ± 0.28‡
HDL3 cholesterol (mmol/l): Men 0.78 ± 0.19 0.70 ± 0.18‡
                                           Women 0.83 ± 0.22 0.76 ± 0.22†
Apolipoprotein A-I (g/l):      Men 1.32 ± 0.20 1.32 ± 0.20*
                                     Women 1.46 ± 0.23 1.41 ± 0.23†
Apolipoprotein B/A-I 0.63 ± 0.20 0.75 ± 0.23‡
Total cholesterol/HDL cholesterol 3.58 (2.91-4.46) 4.30 (3.55-5.60)‡
Triglyceride/HDL cholesterol 0.76 (0.51-1.17) 1.06 (0.73-1.90)‡
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Table 9. Competing risk regression analysis with risk factors for an incident CAD event.
SubHR (95% CI) p-value
eGFR (28 ml/min/1.73 m2) 0.69 (0.58 - 0.84) <0.001
Diabetes duration (11.8 years) 2.39 (2.01 - 2.84) <0.001
Apolipoprotein B (0.23 g/l) 1.40 (1.19 - 1.64) <0.001
Laser treatment (yes, no) 1.61 (1.15 - 2.25) 0.005
Systolic blood pressure (18 mmHg) 1.22 (1.06 - 1.40) 0.005
Results are presented as subdistribution hazard ratios (sub)HRs per SD increase with 95% CI. The model
also included HbA1c, sex, waist-to-hip ratio, natural logarithm of albumin excretion rate, and history of
smoking. Coronary artery disease (CAD) events = 198, controls = 2219 and non-CAD deaths = 104.
The  percentage  of  patients  with  a  history  of  smoking  was  high,  and  this  could  be  a
confounding factor. History of smoking at baseline was univariately associated with CAD,
whereas current smoking was not, and therefore, we chose to include history of smoking
in the multivariate models. In the multivariate model, history of smoking was not
independently associated with CAD events in the entire cohort, unlike several of the lipid
variables. We also performed additional NRI analyses to look at the predictive value of
history of smoking versus ApoB. The NRI was 0.6% (p=0.62) when we added history of
smoking to the multivariate model (including duration of diabetes, eGFR, SBP, retinal
laser treatment, sex, HbA1c, WHR, AER, and ApoB), whereas it was 7.7% (p=0.01) when
ApoB was added to the model.
Different lipid variables predicted an incident CAD event when patients were divided by
sex, renal status, and HbA1c.  In  men,  ApoB  was  the  only  lipid  variable  that  was  an
independent predictor of CAD, whereas in women triglycerides, ApoB/ApoA-I ratio, and
triglyceride/HDL cholesterol ratio were the strongest predictors. In macroalbuminuric
patients, ApoB and non-HDL, LDL, and total cholesterol were the strongest predictors,
whereas ApoB/ApoA-I ratio, triglyceride/HDL cholesterol ratio, triglycerides, and ApoA-I
preformed the best in patients with normal AER. ApoB/ApoA-I, triglyceride/HDL
cholesterol ratio, and triglycerides were also the best predictors in patients with an HbA1c
below the median of the cohort (8.3%), whereas in patients with an HbA1c above  the
median, the same lipid variables as in the macroalbuminuric patients (ApoB, non-HDL
cholesterol, LDL cholesterol, and total cholesterol) were the strongest predictors.
To examine clustering of risk factors, we divided the patients into five groups according to
the  number  of  risk  factors  present.  In  Cox  regression  analysis  with  CAD  events  as  the
dependent and clustering as the independent variable, the HR was not significantly
different from that of the reference group (i.e. those patients without any or with only one
of the five risk factors) for patients with no more than two of any of the five risk factors.
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However, in patients with three or more risk factors, the rise in hazard ratio was clear
(Figure 13).
Figure 13. Cox regression analysis for clusters of risk factors for CAD events. Patients were
stratified  into  groups  according  to  the  presence  of  any  of  the  five  risk  factors  listed  below  at
baseline: 1) Hypertension, defined as either a systolic blood pressure >140 mmHg or a diastolic
blood pressure >80 mmHg (117), 2) presence of renal disease, defined as presence of
microalbuminuria, macroalbuminuria, or end-stage renal disease, or an estimated glomerular
filtration rate <60 ml/min/1.73 m2, 3) exceeding the recommended HbA1c >7.0% (117), 4) current
smoking, or 5) dyslipidemia, defined as total cholesterol >5.0 mmol/l, LDL cholesterol >2.6
mmol/l, triglycerides >1.7 mmol/l, HDL cholesterol <1.0 mmol/l for men, HDL cholesterol <1.3
mmol/l for women (117, 334), or apolipoprotein B > 0.90 g/l (335).
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7 DISCUSSION
7.1 Association between renal disease and lipid profiles
7.1.1 Lipid profiles and eGFR
Patients with type 1 diabetes without complications and good glycemic control often have
similar or even more favorable lipid profiles than the background population (336, 337).
However, we found that patients with type 1 diabetes with an impaired renal function
(eGFR<60 ml/min/1.73 m2) had higher triglycerides, total cholesterol, LDL cholesterol,
and ApoB, and lower HDL cholesterol than patients with eGFR above 60 ml/min/1.73 m2.
Triglycerides were an independent predictor of eGFR in a multiple linear regression
model, whereas LDL cholesterol and HDL cholesterol were not. When triglycerides and
LDL cholesterol were replaced with ApoB, it was also an independent predictor of eGFR.
Previous studies are scarce, but after the publication of our study, associations between
lower HDL cholesterol and impaired renal function were observed in patients with type 1
or type 2 diabetes (338). Higher triglycerides were also seen in patients with type 2
diabetes. In patients with type 2 diabetes, but without macroalbuminuria, higher
ApoB/LDL cholesterol ratio and ApoC-III concentrations have been associated with
impaired renal function regardless of the presence of microalbuminuria (339). In a Korean
study of the general population with 93 228 participants, triglycerides and
triglyceride/HDL cholesterol ratio were the strongest lipid variables associated with
impaired renal function in men, whereas in women LDL cholesterol and non-HDL
cholesterol showed the highest ORs (340).
7.1.2 Lipid profiles and AER
The association between lipid variables and AER in patients with type 1 diabetes has been
examined to a larger extent. In line with our study, triglycerides and total cholesterol were
found  to  be  associated  with  macroalbuminuria  in  the  DCCT/EDIC,  EURODIAB  and
Estudio Diamante cohorts (144, 341, 342). LDL cholesterol was not reported in the
Estudio Diamante Study, but in the other two studies it was also significantly associated
with macroalbuminuria. In our study, HDL cholesterol was significantly lower in patients
with macroalbuminuria, whereas no significant differences were seen between patients
with  normal  AER  or  microalbuminuria.   In  the  EURODIAB  Study,  an  association
between macroalbuminuria and HDL cholesterol was only seen in women and in the
DCCT/EDIC Study, HDL cholesterol was not associated with AER in a multivariate
model. We found that triglycerides, total cholesterol, and ApoB were all significantly
higher  in  patients  with  microalbuminuria.  In  contrast,  in  the  EURODIAB  Study,
triglycerides were the only lipid variable to remain significantly associated with
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microalbuminuria after correcting for multiple confounding factors. ApoB was not
measured in the EURODIAB or Estudio Diamante Studies, but in the DCCT/EDIC Study
it was significantly associated with AER in a multivariate model. Hence, while
dyslipidemia is more evident in advanced diabetic nephropathy, it can be seen to a lesser
degree already at the stage of microalbuminuria.
7.1.3 Normoalbuminuric renal impairment
We observed that 13.4% of patients with eGFR below 60 ml/min/1.73 m2 had normal
AER and 2.3% of patients with normal AER had an eGFR below 60 ml/min/1.73 m2
(Figure 10A and 10B). In previous studies, the frequency of normoalbuminuric renal
impairment in patients with type 1 diabetes has generally varied between 8.3% and 24%
(88, 343, 344). In type 2 diabetes, the most recent studies have found that 36-57% of
patients with impaired renal function are normoalbuminuric (338, 345-349). The
frequency of this condition has increased over the years (350), which may be explained by
the use of more effective medications to treat hypertension (i.e. ACE inhibitors and ARBs)
and hyperglycemia.
It has been speculated that in patients with type 2 diabetes, causes other than the classical
diabetic glomerulosclerosis contribute to the development of normoalbuminuric renal
impairment, e.g. ischemic vascular disease, interstitial fibrosis, or cholesterol
microembolism (351). In support of this, retinopathy and albuminuria were both absent in
as many as 30% of patients with type 2 diabetes and impaired renal function, indicating
other causes of renal disease than true diabetic nephropathy (351). Moreover, resistance of
the intrarenal arteries has been shown to be increased in patients with type 2 diabetes and
impaired renal function, irrespective of albuminuria status (352). However, patients with
type 1 diabetes present a more homogeneous renal phenotype, and the frequency of other
causes of renal disease is substantially lower (353). Further, more advanced diabetic
glomerular lesions were observed in normoalbuminuric patients with type 1 diabetes and
reduced GFR (<90 ml/min/1.73 m2)  than  in  those  with  normal  GFR  (343).   Therefore,
normoalbuminuric renal impairment cannot be solely explained by other causes of renal
disease than diabetic nephropathy. Patients with normoalbuminuric renal impairment are
more frequently women, have less retinopathy, are older, and have shorter diabetes
duration than patients with albuminuric renal impairment (338, 345, 346).
The clinical significance of normoalbuminuric renal impairment has been debated, and the
trait has been suggested to be explained by physiological aging. However, even if
normoalbuminuric renal impairment is likely to be more benign than albuminuric renal
impairment, it is still associated with a significant CVD burden (346), and both eGFR and
AER  have  been  found  to  be  independently  associated  with  mortality  and  progression  to
ESRD (354).
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7.1.4 Achievement of recommended lipid targets
Few patients reached the internationally recommended lipid targets in our study. The
targets were especially poorly met in patients with albuminuria, in patients with impaired
renal function, and in patients without manifest renal disease who had poor glycemic
control, were overweight, or were hypertensive.  Our data suggest that many patients with
type 1 diabetes are in need of lipid-lowering treatment for the prevention of CVD.
7.2 Lipid variables as predictors of progression of renal disease
Lipid abnormalities predicted progression of diabetic nephropathy at all stages of renal
disease. When progression from normo- to microalbuminuria and micro- to
macroalbuminuria was pooled, the overall progression of renal disease was predicted by
triglycerides independently of other risk factors, including both AER and eGFR. When
progression to micro- and macroalbuminuria was analyzed separately, triglycerides
predicted development of incident microalbuminuria or progression to macroalbuminuria,
but when AER was entered into the models triglycerides were no longer an independent
predictor. The definition of renal disease may influence the results. Progression to micro-
or macroalbuminuria was defined based on a change in the degree of albuminuria, and
therefore, AER is already by definition a very strong predictor of progression. The power
was naturally also better in the pooled analysis, especially regarding progression from
micro- to macroalbuminuria, since only 50 patients progressed from micro- to
macroalbuminuria during the follow-up period. ApoB also predicted progression of both
micro- and macroalbuminuria in their respective analyses, but like triglycerides, not
independently of AER.
In the EURODIAB Study, the triglyceride concentration was almost as strong a predictor
as AER for the development of microalbuminuria, with a standardized estimate of relative
risk (SERR) of 1.3 compared with 1.5 for AER (355). Regarding progression to
macroalbuminuria, triglycerides were not an independent predictor of progression, but in
the univariate analyses triglycerides were significantly higher in patients who progressed
to macroalbuminuria and the lowest concentrations were seen in the group that regressed
to normoalbuminuria (356). In the DCCT/EDIC Study, triglycerides, total cholesterol, and
LDL cholesterol were all associated with progression to macroalbuminuria and regression
to normoalbuminuria (357).  In the Pittsburgh EDC Study, LDL cholesterol predicted
development of microalbuminuria in men and in all patients combined, whereas
triglycerides predicted development of microalbuminuria in women and in patients with
diabetes duration of over 20 years (134). In another follow-up study of the same cohort,
triglycerides, LDL cholesterol, and non-HDL cholesterol predicted progression to overt
nephropathy (defined as macroalbuminuria or ESRD) within 5 years, but not in patients
who progressed 6-10 years after baseline (125). In the German Diabetes Documentation
System  Study,  triglycerides  and  LDL  cholesterol  were  significant  risk  factors  for  the
development of microalbuminuria. Furthermore, dyslipidemia, defined as at least one lipid
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variable  above  the  cut-off  thresholds  (total  cholesterol  >200  mg/dl  ≈ 5.2  mmol/l,  LDL
cholesterol >160 mg/dl ≈ 4.1 mmol/l, or triglycerides >150 mg/dl ≈ 1.7 mmol/l), was
associated with progression to macroalbuminuria (358).
In our study, several lipid variables predicted progression from macroalbuminuria to
ESRD, e.g. high total cholesterol, triglycerides, LDL cholesterol, non-HDL cholesterol,
and ApoB/ApoA-I ratio as well as low HDL cholesterol. However, when baseline eGFR
was entered into the model, the only lipid variable that remained an independent predictor
was total  cholesterol.  In a cohort  from the Steno Diabetes Center including patients with
type 1 diabetes and macroalbuminuria at baseline, total cholesterol was significantly
associated with a decline in GFR measured with the Cr-EDTA plasma clearance technique
(359). Triglycerides predicted renal failure in the World Health Organization
Multinational  Study  of  Vascular  Disease  in  Diabetes  (WHO-MSVDD)  in  patients  with
type  2  diabetes,  but  not  in  patients  with  type  1  diabetes  (360).  However,  the  power  was
much lower in patients with type 1 diabetes (only 53 vs. 134 events in patients with type 1
and type 2 diabetes, respectively), and triglycerides were only measured in a subset of the
participating study centers, decreasing the power even further. In the DCCT/EDIC Study,
lipid variables did not predict the development of impaired eGFR (<60 ml/min/1.73 m2)
(357), however, in the Swedish National Diabetes Register (NDR) Study of patients with
type 2 diabetes, triglycerides were independently associated with the development of
impaired eGFR (361).
When we divided the patients into quartiles of the triglycerides, the highest quartile had
the highest HR for progression of renal disease at all stages (see Figure 1 in Study II).
Moreover, the hazard ratio for the development of incident microalbuminuria increased
significantly with every quartile. It is noteworthy that the cut-off levels for the triglyceride
quartiles were much lower than the recommended cut-off threshold of <1.7 mmol/l in the
current treatment guidelines. In ROC curve analyses of triglycerides for the prediction of
renal disease development and progression (see Study II Supplementary Figures 1A-C)
and in Figures 12A and 12B, no clinically relevant thresholds for triglycerides with regard
to the progression of renal disease emerged.
It is, however, difficult to ascertain causal links based on these data since repeated lipid
and AER measurements from the day of diabetes diagnosis are not available. Whether the
lipid abnormalities are primary and consistently precede the development of renal disease
or are merely a consequence of renal disease has been widely debated and remains
unknown. However, based on the findings from the above prospective studies, and the fact
that favorable lipid profiles are associated with regression of microalbuminuria (362) and
dyslipidemia with faster progression of renal disease (125, 363-366), there is an evident
clinical message: dyslipidemia is associated with a poorer prognosis, especially if other
risk factors, such as hyperglycemia, hypertension, smoking, and obesity, are
simultaneously present.
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7.3 Lipid profiles and diabetic retinopathy
In univariate analyses, multiple associations between lipid variables and PDR emerged,
but in the multivariate models after correction for confounding factors, e.g. renal disease
and HbA1c,  only  HDL  cholesterol  and  HDL2 cholesterol were independently associated
with PDR. When only patients without retinopathy or mild NPDR were included in the
analyses, triglycerides and triglyceride/HDL cholesterol ratio were associated with mild
NPDR independently of confounding factors. These results are in line with some of the
previous studies. In the EURODIAB Study, triglycerides were independently associated
with  both  moderate  to  severe  NPDR  and  PDR  (20).  In  the  DCCT/EDIC  Study,  the
severity of retinopathy was inversely associated with HDL cholesterol and VLDL size and
positively associated with triglycerides and small- and medium-sized VLDL (367). Some
earlier studies report significant associations between diabetic retinopathy and total
cholesterol or LDL cholesterol (17, 368), but we only found significant associations in the
univariate analyses. However, there are also several studies in which no associations
between lipid variables and retinopathy status have been found (18, 19, 369).
Among prospective studies, triglycerides were independently associated with the
development  of  retinopathy  in  the  EURODIAB Study (370)  and  with  the  progression  of
retinopathy in the Pittsburgh EDC Study (371). However, lipid variables were not
predictive of progression of PDR in the Sorbinil Retinopathy Trial (372) nor in the DCCT
Study (373).
It is difficult to compare these studies with each other because of differing methods for
detection of diabetic retinopathy, differences in the definition of retinopathy, differences
in sizes of the study cohorts, and differing degree of nephropathy and availability of other
risk factors for multivariate models. Relative to the strength of the associations between
hyperglycemia and retinopathy and between lipid variables and CVD, the associations
between lipids and retinopathy are clearly weaker, and it is impossible to draw any
definite conclusions.
However, a consensus can be found regarding the association between serum lipid levels
and hard exudates. Hard exudates are usually the consequence of lipid leakage from
dysfunctional retinal capillaries and are considered an early sign of diabetic retinopathy
and  are  also  typically  associated  with  maculopathy.  In  the  WESDR  Study,  total
cholesterol was significantly associated with the presence and severity of hard exudates
(369), and in the ETDRS Study total and LDL cholesterol were also associated with hard
exudates (374). In studies including mostly patients with type 2 diabetes, such as the
Hoorn Study (375) and the Atherosclerosis Risk in Communities (ARIC) Study (376),
associations between lipid variables and hard exudates were also confirmed.
The presence or absence of diabetic nephropathy is probably the most important
confounding factor and a driving force behind the conflicting results in the studies
exploring the associations between diabetic retinopathy and lipid variables. Similar
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mechanisms and risk factors are thought to be behind the development of both diabetic
retinopathy and nephropathy, and it is therefore no surprise that the two complications are
strongly associated with each other (16). Diabetic nephropathy may lead to secondary
changes in the lipid profile, and thus, it is difficult to determine whether the associations
between retinopathy and the lipid variables are independent or they simply reflect the
association between nephropathy and retinopathy. Therefore, multivariate models that take
renal disease into account are needed, although one cannot be sure that this will eliminate
the problem entirely. Notably, we found interactions between retinopathy, nephropathy,
and several of the lipid variables. Due to our large cohort, we were also able to separately
analyze patients with normal AER and eGFR >60 ml/min/1.73 m2. Significant differences
were seen in the total cholesterol/HDL cholesterol ratio by retinopathy status groups, and
differences of borderline significance (p<0.05) emerged for several of the lipid variables.
Clearly, associations between lipid variables and retinopathy are weaker when renal
disease is taken into account, but there is also a risk for over-correction. Indeed 85% of
our  patients  with  PDR  also  had  some  signs  of  renal  disease,  and  by  excluding  these
patients from the analyses the group is no longer representative of the normal clinical
setting.
To explore this dilemma from another angle, we looked at the correlations between AER
and the lipid variables divided by the retinopathy status. In patients with moderate to
severe NPDR or PDR, significant correlations between AER and the lipid variables were
seen, as expected. However, in the patients without retinopathy, no significant correlations
between AER and lipid variables were observed, and in the patients with mild NPDR only
a few fairly weak correlations were present. Further, we found that in the patients without
retinopathy or with only mild NPDR, AER was in fact low despite having unfavorable
lipid profiles (i.e. HDL cholesterol in the lowest quartile or triglycerides, total cholesterol,
or LDL cholesterol in the highest quartile). Importantly, retinopathy cannot cause
secondary changes in the lipid profile so there has to be another explanation for this
phenomenon. Possibly, some patients are protected from the unfavorable effects of lipid
variables on microvascular complications. In contrast, the presence of severe retinopathy
could serve as a marker for a more deleterious effect of hyperlipidemia and other risk
factors on renal outcomes. In support of this theory, the EURODIAB Study found
different associations between the blood pressure and AER in patients with and without
retinopathy (377).
In light of these findings, it seems unwise to expect that the associations between lipid
variables and retinopathy would be totally independent of renal disease. Furthermore, in
contrast to HDL cholesterol, SBP was not independently associated with PDR when AER
and eGFR were included in the multivariate model. Nevertheless, there is strong evidence
for a causal relationship between blood pressure and progression of diabetic retinopathy
from randomized clinical trials (165, 378).
Another problematic confounding factor is hyperglycemia. Associations exist between
lipid variables and hyperglycemia, especially between triglycerides and hyperglycemia.
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Again, multivariate models can take into account the confounding factors, but they cannot
provide definite proof of an independent role of the factor studied. Moreover, it is not
possible to draw any conclusions about a causal relationship from cross-sectional studies.
Even prospective studies often have many confounding factors; hence, conclusions should
be drawn with caution. Randomized clinical trials are needed to show a causal
relationship. In the FIELD Trial, fenofibrate treatment reduced the need for the first laser
treatment, and in the ACCORD Study patients who received fenofibrate on top of
simvastatin treatment had a reduced rate of progression of diabetic retinopathy.
Fenofibrate mainly reduces triglycerides and increases HDL cholesterol concentrations,
however, in the FIELD Study the beneficial effect of fenofibrate did not seem to be related
to  any  changes  in  the  lipid  concentrations.  In  the  ACCORD  Study,  a  clinically  relevant
decrease in triglycerides and increase in HDL cholesterol concentrations were seen in
patients treated with fenofibrate compared with simvastatin alone, but the beneficial
mechanism of fenofibrate remains unclear.
7.4 Lipid variables as predictors of a CAD event
In this study we showed that ApoB was the strongest independent predictor of an incident
CAD event in the entire FinnDiane population. Triglycerides, non-HDL cholesterol,
ApoB/ApoA-I ratio, and lipid ratios were also good predictors of an incident CAD event.
Previous data from prospective studies in patients with type 1 diabetes are surprisingly
scarce. In the EURODIAB Study, triglycerides and HDL cholesterol were independent
predictors of CAD in separate models (379) after a 7-year follow-up. In the 10-year
follow-up  data  from  the  Pittsburgh  EDC  Study,  HDL  cholesterol  and  non-HDL
cholesterol predicted CAD events (380). In a Danish study, triglycerides, LDL cholesterol,
and HDL cholesterol were all related to CAD after 13 years of follow-up (381). Finally, in
the WHO-MSVDD Study, total cholesterol predicted the incidence of myocardial
infarction in patients with type 2 diabetes, but not in patients with type 1 diabetes (382).
When men and women were analyzed separately, we found that ApoB was the strongest
lipid predictor in men, whereas triglycerides, ApoB/ApoA-I ratio, and triglyceride/HDL
cholesterol ratio had the highest HR per SD increase in women (see Study IV
Supplementary  Table  4).  In  the  EURODIAB Study,  triglycerides  also  predicted  CAD in
women. However, in that study, apolipoproteins were not measured and lipid ratios were
not calculated.
The predictive performance of LDL cholesterol in this study was poor. In the entire
cohort, the NRI for LDL cholesterol was 3.2%, compared with 7.7% for ApoB. Moreover,
in patients without renal disease, LDL cholesterol was not an independent predictor of
CAD, and Figure 1A (in Study IV) shows that the median LDL cholesterol level was not
able to separate cases from controls. Further, in patients with HbA1c below 8.3% and in
women, LDL cholesterol could not predict CAD independently of other risk factors.
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Experimental studies have shown that remnant cholesterol accumulates in the arterial wall
like LDL cholesterol (383, 384), and importantly, both ApoB and non-HDL cholesterol
are capturing the risk of all the atherogenic particles, including the VLDL, IDL, and LDL.
Of note, the mean baseline LDL cholesterol concentration (3.45 mmol/l) of patients with
an incident CAD event in this study was lower than the mean LDL cholesterol
concentrations  in  older  clinical  trials  of  lipid-lowering  treatment  (385).  In  addition,  the
presence of sdLDL particles is not revealed by LDL cholesterol concentrations. ApoB is a
better detector of an increased number of sdLDL particles (see also Section 2.3.2), and in
concordance, ApoB was a stronger predictor of CAD than LDL cholesterol in our study.
Furthermore, already in children with type 1 diabetes a preponderance of sdLDL
compared with children without diabetes has been reported (238). There are also several
limitations regarding the LDL cholesterol calculated by the Friedewald formula. The best
known is the underestimation of LDL cholesterol in hypertriglyceridemic conditions. LDL
cholesterol should not be calculated using this formula in patients with triglyceride
concentrations above 4.0 mmol/l, but as a consequence, several high-risk patients (N=48)
could not be included in the multivariate models with LDL cholesterol as the lipid
variable. Concerns have also been raised about the accuracy of the Friedewald LDL
cholesterol at much lower triglyceride concentrations (386, 387) it has been found to
underestimate LDL cholesterol concentrations already when triglycerides exceeds 1.7
mmol/l  (388).  Of  note,  also  in  previous  prospective  studies  in  patients  with  type  1
diabetes, other lipid variables have emerged as better predictors of CAD events than LDL
cholesterol (379, 380). Data from randomized clinical trials have established LDL
cholesterol lowering as the primary target of therapy for prevention of CAD, but the
residual risk present beyond that of LDL cholesterol should be recognized in clinical
practice, especially in patients with type 1 diabetes with fairly good glycemic control, in
patients without renal disease, and in women.
In this study, HDL cholesterol was a weaker predictor of CAD than atherogenic lipid
variables. Its best performance was seen in patients with normal AER at baseline;
however, also in these patients, triglycerides and ApoA-I were stronger predictors of
CAD. The relationship between HDL cholesterol and CAD is far more complex than
initially assumed. Despite the strong inverse correlation between HDL cholesterol and
CAD seen in epidemiological studies, a pharmacological increase of HDL cholesterol has
failed to reduce the risk of CAD. Further, a Mendelian randomization study showed that a
genetic mechanism that raised HDL cholesterol did not lower the risk of myocardial
infarction, thereby calling into question the assumed causal relationship between low HDL
cholesterol concentrations and CAD risk (389). From clinical practice, we know that low
HDL cholesterol is rarely an isolated trait and is most often accompanied by increased
triglycerides, abdominal obesity, and other components of metabolic syndrome. Therefore,
we may have jumped to a conclusion by assuming a causal relationship between reduced
HDL cholesterol and CAD risk. The poorer performance of HDL cholesterol compared
with atherogenic variables could also be related to changes in functionality and a possible
loss of protective effects of HDL cholesterol in patients with type 1 diabetes. The possible
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functionality changes cannot be captured by the mere measurement of HDL cholesterol
concentrations or lipid ratios, but interestingly, the lipid and lipoprotein ratios containing
atherogenic and anti-atherogenic particles were among the strongest predictors of CAD in
women and in healthier patients (i.e.  patients without renal disease or with HbA1c below
8.3%). By contrast, in patients with renal disease, in patients with HbA1c above 8.3%, or in
men, no additional benefit was gained from the ratios compared with the atherogenic lipid
variables alone.
The frequency of patients with a history of smoking was high in the cohort, but the
frequency of current smoking at baseline was much lower. Current smoking was not
univariately associated with CAD events, whereas history of smoking was, and therefore
history of smoking was chosen for the multivariate models. However, history of smoking
was not an independent predictor of CAD, whereas several lipid variables were.
Therefore, in this study smoking did not explain the high CAD risk any better than did
lipid variables; however, both are definitely important risk factors that should be treated
aggressively and are likely to have a potentiating effect. A dual increase in chronic
inflammation could, for example, be one of the driving mechanisms for a potentiating
effect.
When we performed a Cox regression analysis with clustering of risk factors as the
independent variable, we could see that the rise in HR was not linear. For patients with no
more than two of any of the five risk factors, the HR was not significantly different from
that of the reference group. However, in patients with three risk factors the HR was
already 3.27, in patients with four risk factors the HR was 5.96, and in those with all five
risk factors the HR was 7.02 compared with the reference group. Our results indicate a
potentiating effect with an increasing number of risk factors in patients with three or more
risk factors.
The metabolic syndrome is a cluster of risk factors dominated by central obesity, increased
triglycerides, decreased HDL cholesterol, and elevated blood pressure. In this study,
eGDR, a formula for insulin sensitivity that includes WHR, HbA1c , and hypertension, was
clearly lower in patients with CAD than in controls (4.49 vs. 6.90 mg/kg/min). In the
Pittsburgh EDC cohort, eGDR was shown to predict lower extremity arterial disease
(390), macroalbuminuria (125), and hard CAD events (380).
7.5 Strengths and limitations
The patients in Studies I,  II,  and IV account for roughly 10% of all  patients with type 1
diabetes in Finland and show even distribution geographically, closely following the
distribution of the general population in Finland (see Figure 8). A selection bias is
therefore less likely than in single hospital-based studies. Furthermore, the high response
rate of 78% (325) makes any significant selection biases unlikely. An additional strength
is that all lipid variables were measured in the same laboratory specializing in lipid
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research and that the phenotypes for diabetic nephropathy, retinopathy, and CAD were
robustly and meticulously assessed. Thus, this large cohort is unique for the detailed study
of lipid profiles of patients with type 1 diabetes.
A limitation  of  Studies  I  and  III  was  the  cross-sectional  study  design;  however,  Study  I
was followed by a subsequent prospective study. In Study III, the retinopathy status was
determined in 1465 consecutively recruited patients with complete lipid profiles. To avoid
a selection bias, the patients were derived from the first patients participating in the
FinnDiane  Study.  In  Study  II,  the  progression  of  renal  disease  was  ascertained  after  a
review of the medical files, and therefore, the follow-up information was not dependent on
patients’ participation in a revisit, only on their regular visits to their physician. In Study
IV, the follow-up information on CAD events was obtained from the Finnish Hospital
Discharge Register as well as the Causes of Death Register; hence, follow-up information
was available for all patients. A limitation of the studies is the possible survival bias,
however, this was accounted for by performing competing risk regression analyses in
Study IV.
Another limitation of the study is that it is not feasible to measure the GFR directly in such
a large cohort. In Study I, we used the Cockcroft-Gault formula (71). This formula was
developed in a population of hospitalized men with a fairly wide range of renal function.
Because the estimate also includes the tubular secretion of creatinine, it has been found to
systematically overestimate the actual renal function (391). In Study II, we used both the
Cockcroft-Gault and the MDRD-4 equation (72).  The MDRD equation was developed in
patients with chronic kidney disease. It has been validated in Caucasian populations aged
between 18 and 70 years with eGFR <60 ml/min/1.73 m2 and has shown good
performance for patients with impaired renal function. However, the MDRD equation has
been found to be less accurate in populations without impaired renal function (392, 393).
The CKD-EPI equation (73) is the newest of the eGFR equations and was used in Study
IV. It was developed in a population with a wide range of measured GFR to address the
issue  of  underestimation  of  eGFR  by  the  MDRD  equation  at  eGFR  levels  above  60
ml/min/1.73 m2.  The CKD-EPI equation has been found to be as accurate as the MDRD
equation when GFR is <60 ml/min/1.73 m2 and more accurate when GFR is between 60
and 120 ml/min/1.73 m2 (73).
Unfortunately, renal biopsies were not available from our patients. However, in patients
with type 1 diabetes, the renal phenotype is much more homogeneous than in patients with
type 2 diabetes (353) as previously discussed in Section 7.1.3. The presence of retinopathy
is also considered to support the diagnosis of diabetic nephropathy (394). In our patients
with ESRD, 98.5% had a history of laser treatment,  which is performed to treat  PDR or
severe NDPR in the vast majority of patients (161).
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7.6 Lipid variables and micro- and macrovascular complications
Triglycerides were associated with AER, eGFR, and mild NPDR and predicted the
progression of renal disease at all stages of albuminuria and incident CAD events in the
total population, in women, and in patients with normal AER. Triglyceride concentrations
have been shown to be strongly related to glycemic control (337), and it is widely known
that corrections of severe hyperglycemia will also lead to lower triglycerides. However, in
all four studies, triglycerides were associated with or predicted adverse events
independently of HbA1c. Furthermore, triglycerides were not the only lipid variable
associated with adverse microvascular events, for example, ApoB also predicted
progression to micro- and macroalbuminuria, total cholesterol predicted progression to
ESRD, and HDL cholesterol was associated with PDR. Therefore, our results support an
additive effect of triglycerides and other lipid variables on microvascular complications
beyond glycemic control.
Triglycerides are often a univariate predictor of CVD, but not an independent predictor
when the multivariate models are adjusted with other lipid variables, which is probably
due to the strong correlations between triglycerides and both non-HDL cholesterol and
HDL cholesterol (335). A study from the Emerging Risk Factor Collaboration (ERFC)
including 68 prospective studies, with individual data from a total of 302 430 participants,
showed that triglycerides were not an independent predictor of CAD after adjustments for
HDL and non-HDL cholesterol, whereas HDL cholesterol and non-HDL cholesterol
remained independent predictors after the adjustments (395). In addition, there is no
evidence from clinical trials that lowering triglycerides reduces CVD events after
adjusting for HDL cholesterol. However, a genetic association study showed that
triglycerides are a causal risk factor of CAD independently of HDL and LDL cholesterol,
whereas genetic variants primarily associated with HDL cholesterol were not associated
with CAD after adjustments with triglycerides and LDL cholesterol (396) (see also
discussion in Section 7.4). Importantly, increased triglyceride concentrations are
associated with higher remnant cholesterol concentrations (i.e. VLDL and IDL cholesterol
as well as chylomicron remnants in the non-fasting state). A causal association between
increased remnant cholesterol concentrations and both CAD and low-grade inflammation
was shown in a Mendelian randomization study, whereas increased LDL cholesterol
concentrations were causally associated with CAD, but not with inflammation (397). LDL
cholesterol will remain the primary treatment target due to strong evidence from clinical
trials, but increasing evidence highlights the superiority of either non-HDL cholesterol or
ApoB over LDL cholesterol for CVD risk prediction (398-400). However, expert opinion
is divided regarding whether or not apolipoprotein measurements should replace
cholesterol measurements, and the evidence is conflicting. The ERFC Study found that
non-HDL/HDL cholesterol and ApoB/ApoA-I ratios had very similar HR for CAD (395),
whereas in a meta-analysis including 233 455 participants the mean relative risk ratio for
ApoB  was  12%  higher  than  for  LDL  cholesterol  and  6%  higher  than  for  non-HDL
cholesterol (401). The conflicting results could be caused by differences between study
populations and in the proportions of patients with metabolic dyslipidemia (i.e. high
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triglycerides, low HDL cholesterol, and sdLDL cholesterol) included in the studies, and it
has been suggested that ApoB may be a better CVD predictor in these patients (402).  In
our study, the HR of ApoB and non-HDL cholesterol for CAD events was 1.40 and 1.27,
respectively, and in the NRI analyses ApoB correctly reclassified more patients than non-
HDL cholesterol when it was added to the multivariate model (7.7% [p=0.01] vs. 4.7%
[p=0.06]). All in all, the difference between non-HDL cholesterol and ApoB seems to be
small at least in the general population, and the clear benefits of calculating non-HDL
cholesterol lie in its good clinical availability and in creation of no additional costs when
total cholesterol and HDL cholesterol have been measured. On the other hand, ApoB
measurements have become less expensive, their clinical availability has improved, and
computationally estimated ApoB with strong correlations (r=0.93-0.98) and no additional
costs has been developed (403). As both non-HDL cholesterol and ApoB perform better
than LDL cholesterol, the use of either one in the clinical setting should be emphasized in
order to capture residual CAD risk.
7.7 Lipid profiles in patients with “double diabetes”
Importantly, in patients with renal disease, poor glycemic control, or high BMI, as seen in
Study  I,  the  lipid  profile  resembles  that  of  patients  with  type  2  diabetes.  We  have
previously shown that the weight-adjusted insulin dose tends to be similar or even higher
in such patients (404),  which suggests that  the dyslipidemia is more related to increased
insulin resistance than to inadequate insulin administration. The concept of “double
diabetes” (i.e. when patients with type 1 diabetes exhibit features of type 2 diabetes and
insulin resistance) has been proposed to describe this phenomenon (405). The prevalence
of double diabetes is increasing as a consequence of increased adiposity worldwide, and
the  prevalence  of  metabolic  syndrome  in  the  FinnDiane  cohort  is  as  high  as  40%  in
women and 38% in men (230). The triglyceride/HDL cholesterol ratio, which strongly
correlates with insulin resistance (406), predicted progression to macroalbuminuria and
ESRD in Study II, was associated with retinopathy in Study III, and predicted CAD events
in the entire cohort, in women, in patients with normal AER, and in patients with HbA1c
below the median of the cohort in Study IV. These data are supported by the DCCT Study,
in which eGDR, an estimate of insulin sensitivity, strongly predicted the development of
nephropathy, retinopathy, and CVD (232).
7.8 Lipid thresholds and prediction
Cut-off values are widely used in the clinical setting, however, many continuous
biological risk factors lack clear thresholds. This is also true for the lipid variables. In our
study we could not find any clinically relevant thresholds for any of the lipid variables
with regard to either micro- or macrovascular complications. However, the currently
recommended cut-off level (<1.7 mmol/l) for triglycerides seems to be too high for
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patients with type 1 diabetes with regard to renal disease progression and prediction of an
incident CAD event. However, the cut-off of 1.7 mmol/l derives from studies for the
prevention of cardiovascular disease in the general population. Thus, the cut-off for
prediction of renal disease progression is unknown, but it is also noteworthy that the
currently  recommended  cut-off  level  was  unable  to  predict  an  incident  CAD  event  in
patients with normal AER. AER is also a continuous risk factor for micro- and
macrovascular complications, and even a mild increase within the normoalbuminuric
range predicts adverse outcomes (407, 408). Therefore, it has been proposed that we
should cease to use the traditional categories of normo-, micro-, and macroalbuminuria
and aim for an earlier risk evaluation by a multifactorial approach. Studies of renal
biopsies from patients with type 1 and type 2 diabetes also support this notion (353).
7.9 Multifactorial approach
Multiple risk factors often cluster in the same patients.  In Study IV, we showed that the
increase  in  HR  for  incident  CAD  events  was  not  linear,  and  an  additive  effect  with
increasing number of risk factors in patients with three or more risk factors was seen.
From a practical point of view, risk calculators are needed for clinicians to be able to take
into account multiple and continuous risk factors. Many calculators already exist for the
prediction of CVD, but few are specifically designed for patients with type 1 diabetes, and
risk calculators for prediction of renal disease are even scarcer. A multifactorial approach
is also needed for the prevention of both micro- and macrovascular complications. In the
Steno-2 Study, including patients with type 2 diabetes and microalbuminuria at baseline,
160 patients were randomized to receive either conventional or intensified multifactorial
treatment (188). Intensified treatment included both lifestyle modifications and
pharmacological treatments and reduced, for example, total cholesterol by 50 mg/dl ≈ 1.3
mmol/l, triglycerides by 41 mg/dl ≈ 0.5 mmol/l, SBP by 14 mmHg, and HbA1c by 0.5%.
After 7.8 years of follow-up, intensified treatment reduced the risk of CVD events by
53%, progression to macroalbuminuria by 61%, and development or progression of
retinopathy by 58%. Experimental studies also support a multifactorial pharmacological
approach. In rats with massive proteinuria and renal lesions,  the combination of an ACE
inhibitor and a statin significantly reduced glomerulosclerosis, interstitial inflammation,
and tubular damage, more than the effect of either drug alone (318). However, it is quite
clear that more randomized clinical trials are still needed to clarify the role of lipid
variables and lipid-lowering treatment in the prevention of microvascular complications.
We still lack large trials with multifactorial approaches that are initiated at an early stage
of the disease process, take into account concomitant microvascular complications, and
include a sufficient number of patients and sufficiently long follow-up periods.
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8 SUMMARY AND CONCLUSIONS
8.1 Study I
In patients with type 1 diabetes, not only increased AER but also impaired renal function
(eGFR<60 ml/min/1.73 m2) is associated with lipid abnormalities. Changes in the lipid
profile can be seen already at the stage of microalbuminuria, but are more evident in
patients with macroalbuminuria. A number of patients in this study would have exceeded
the internationally recommended lipid targets for the prevention of CVD, and the targets
were particularly poorly met with respect to the LDL cholesterol concentrations. In
patients with type 1 diabetes and impaired renal function or macroalbuminuria, the targets
were especially poorly met, even though these are the patients who should be treated most
aggressively.  Further,  patients  without  signs  of  renal  disease,  but  with  poor  glycemic
control, hypertension, or obesity also frequently exceeded the recommended lipid targets.
8.2 Study II
Triglycerides were an independent risk factor for the development or progression of renal
disease at all stages. ApoB was also an independent predictor of progression to micro- and
macroalbuminuria. Total cholesterol predicted progression from macroalbuminuria to
ESRD independently of eGFR. The triglyceride concentration needed to increase the risk
of progression of renal disease was much lower than the currently recommended cut-off
level for triglycerides (<1.7 mmol/l), which is based on studies aimed at preventing
cardiovascular disease. When ROC curves and predicted probability plots were performed,
no clinically relevant thresholds emerged, but whether lower lipid targets than those
currently  recommended  for  CVD  would  be  beneficial  with  regard  to  the  progression  of
renal disease remains to be elucidated.
8.3 Study III
The total HDL and HDL2 cholesterol concentrations were inversely associated with PDR
independently of diabetes duration, metabolic control, blood pressure, and renal disease.
The triglycerides were independently associated with mild NPDR. We observed
interactions between retinopathy, nephropathy, and most lipid variables. The previously
reported associations between AER and lipid variables were not seen in patients without
signs of retinopathy. Furthermore, the correlations between AER and lipid variables were
much  stronger  in  patients  with  PDR  than  in  patients  with  only  mild  NPDR.  The  results
were also replicated in an independent cohort of 1100 patients with information on laser
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treatment available. The results suggest the existence of shared pathological mechanisms
between diabetic retinopathy and nephropathy.
8.4 Study IV
The predictive ability of lipid variables differed substantially depending on the patient’s
sex, renal status, and glycemic control and was substantially different from the traditional
cholesterol-centric view. Total and LDL cholesterol were poor predictors of an incident
CAD event in patients with normal AER, in patients with HbA1c below the median of the
cohort, and in women, in whom the ratios of atherogenic and anti-atherogenic lipoproteins
and lipids as well as triglycerides performed better. The current guidelines may need to be
revised to capture residual CAD risk in patients with type 1 diabetes.
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APPENDIX
The Finnish Diabetic Nephropathy Study
Centers
Physicians and nurses
Anjalankoski Health Center S. Koivula, T. Uggeldahl
Central Finland Central Hospital, Jyväskylä
T. Forslund, A. Halonen, A.
Koistinen, P. Koskiaho, M.
Laukkanen, J. Saltevo, M. Tiihonen
Central Hospital of Åland Islands, Mariehamn M. Forsen, H. Granlund, A-C.Jonsson, B. Nyroos
Central Hospital of Kanta-Häme, Hämeenlinna P. Kinnunen, A. Orvola, T. Salonen,A. Vähänen
Central Hospital of Kymenlaakso, Kotka R.  Paldanius, M. Riihelä, L. Ryysy
Central Hospital of Länsi-Pohja, Kemi H. Laukkanen, P. Nyländen, A.Sademies
Central Ostrabothnian Hospital District, Kokkola
S. Anderson, B. Asplund, U.
Byskata, M. Kuusela, P. Liedes, T.
Virkkala
City of Espoo Health Centre:
-Espoonlahti A. Nikkola, E. Ritola
-Samaria E. Oukko-Ruponen, T. Virtanen
-Tapiola M. Niska, H. Saarinen
-Viherlaakso A. Lyytinen
City of Helsinki Health Centre:
-Puistola H. Kari, T. Simonen
-Suutarila A. Kaprio, J. Kärkkäinen, B.Rantaeskola
-Töölö J. Haaga, P. Kääriäinen, A-L.Pietiläinen
City of Hyvinkää Health Centre S. Klemetti, T. Nyandoto, E. Rontu,S. Satuli-Autere
City of Vantaa Health Centre:
-Korso R. Toivonen, H. Virtanen
-Länsimäki R. Ahonen, M. Ivaska-Suomela, A.Jauhiainen
-Martinlaakso M. Laine, T. Pellonpää, R. Puranen
-Myyrmäki A. Airas, J. Laakso, K. Rautavaara
-Rekola M. Erola, E. Jatkola
-Tikkurila R. Lönnblad, A. Malm, J. Mäkelä, E.Rautamo
Heinola Health Centre P. Hentunen, J. Lagerstam
Helsinki University Central Hospital,
Department of Medicine, Division of
Nephrology
M. Feodoroff, C. Forsblom, D.
Gordin, V. Harjutsalo, K. Hietala, J.
Kytö, M. Parkkonen, M. Rahkonen,
M. Rosengård-Bärlund, A.-R.
Salonen, L. Salovaara, A. Sandelin,
M. Saraheimo, T. Soppela, A. Soro-
Paavonen, L. Thorn, J.
Tuomikangas, J. Wadén
Herttoniemi Hospital, Helsinki V. Sipilä
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Hospital of Lounais-Häme, Forssa
T. Kalliomäki, J. Koskelainen, R.
Nikkanen, N. Savolainen, H.
Sulonen, E. Valtonen
Hyvinkää Hospital A. Hämäläinen, L. Norvio
Iisalmi Hospital E. Toivanen
Jokilaakso Hospital, Jämsä A. Parta, I. Pirttiniemi
Jorvi Hospital, Helsinki University Central
Hospital
S. Aranko, S. Ervasti, R. Kauppinen-
Mäkelin, A. Kuusisto, T. Leppälä, K.
Nikkilä, L. Pekkonen
Jyväskylä Health Centre, Kyllö K. Nuorva, M. Tiihonen
Kainuu Central Hospital, Kajaani S. Jokelainen, P. Kemppainen, A-M.Mankinen, M. Sankari
Kerava Health Centre H. Stuckey, P. Suominen
Kirkkonummi Health Centre A. Lappalainen, M. Liimatainen, J.Santaholma
Kivelä Hospital, Helsinki A. Aimolahti, E. Huovinen
Koskela Hospital, Helsinki V. Ilkka, M. Lehtimäki
Kotka Heath Centre E. Pälikkö-Kontinen, A. Vanhanen
Kouvola Health Centre E. Koskinen, T. Siitonen
Kuopio University Hospital
E. Huttunen, R. Ikäheimo, P.
Karhapää, P. Kekäläinen, T. Lakka,
M. Laakso, E. Lampainen, L.
Moilanen, L. Niskanen, U. Tuovinen,
I. Vauhkonen, E. Voutilainen
Kuusamo Health Centre E. Isopoussu, T. Kääriäinen
Kuusankoski Hospital E. Kilkki, I. Koskinen, L. Riihelä
Laakso Hospital, Helsinki T. Meriläinen, P. Poukka, R.Savolainen, N. Uhlenius
Lahti City Hospital A. Mäkelä, M. Tanner
Lapland Central Hospital, Rovaniemi L. Hyvärinen, S. Severinkangas, T.Tulokas
Lappeenranta Health Centre P. Linkola, I. Pulli
Lohja Hospital T. Granlund, M. Saari, T. Salonen
Loimaa Health Centre P. Eloranta, A. Mäkelä
Länsi-Uusimaa Hospital, Tammisaari I-M. Jousmaa, J. Rinne
Malmi Hospital, Helsinki H. Lanki, S. Moilanen, M. Tilly-Kiesi
Mikkeli Central Hospital A. Gynther, R. Manninen, P.Nironen, M. Salminen, T. Vänttinen
Mänttä Regional Hospital A-M. Hänninen, I. Pirttiniemi
North Karelian Hospital, Joensuu
U-M. Henttula, P. Kekäläinen, M.
Pietarinen, A. Rissanen, M.
Voutilainen
Nurmijärvi Health Centre A. Burgos, K. Urtamo
Oulankangas Hospital, Oulainen E. Jokelainen, P-L. Jylkkä, E.Kaarlela, J. Vuolaspuro
Oulu Health Centre L. Hiltunen, R. Häkkinen, S.Keinänen-Kiukaanniemi
Oulu University Hospital R. Ikäheimo
Päijät-Häme Central Hospital
H. Haapamäki, A. Helanterä, S.
Hämäläinen, V. Ilvesmäki, H.
Miettinen
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Palokka Health Centre P. Sopanen, L. Welling
Pieksämäki Hospital V. Javtsenko, M. Tamminen
Pietarsaari Hospital M-L. Holmbäck, B. Isomaa, L.Sarelin
Pori City Hospital P. Ahonen, P. Merensalo, K. Sävelä
Porvoo Hospital M. Kallio, B. Rask, S. Rämö
Raahe Hospital A. Holma, M. Honkala, A.Tuomivaara, R. Vainionpää
Rauma Hospital K. Laine, K. Saarinen, T. Salminen
Riihimäki Hospital P. Aalto, E. Immonen, L. Juurinen
Salo Hospital A. Alanko, J. Lapinleimu, P. Rautio,M. Virtanen
Satakunta Central Hospital, Pori
M. Asola, M. Juhola, P. Kunelius, M-
L. Lahdenmäki, P. Pääkkönen, M.
Rautavirta
Savonlinna Central Hospital E. Korpi-Hyövälti, T. Latvala, E.Leijala
South Karelia Central Hospital, Lappeenranta T. Ensala, E. Hussi, R. Härkönen, U.Nyholm, J. Toivanen
Tampere Health Centre
P. Alarotu, L. Calonius, S.
Gummerus , M. Helin, T. Kaitala, H.
Kirkkopelto-Jokinen, E. Kujansuu, T.
Niskanen,  A. Vaden, T. Vatanen
Tampere University Hospital
I. Ala-Houhala, T. Kuningas, P.
Lampinen, M. Määttä, H. Oksala, T.
Oksanen, K. Salonen, H. Tauriainen,
S. Tulokas
Tiirismaa Health Centre, Hollola T. Kivelä, L, Petlin, L. Savolainen
Turku Health Centre I. Hämäläinen, H. Virtamo, M.Vähätalo
Turku University Central Hospital
K. Breitholz, R. Eskola, K.
Metsärinne, U. Pietilä, P. Saarinen,
R. Tuominen, S. Äyräpää
Vaajakoski Health Centre K. Mäkinen, P. Sopanen
Vaasa Central Hospital S. Bergkulla, U. Hautamäki, V-A.Myllyniemi, I. Rusk
Valkeakoski Regional Hospital T. Immonen, S. Ojanen, M.Rautiainen, E. Valtonen, H. Ylönen
Vammala Regional Hospital I. Isomäki, R. Kroneld, M.Tapiolinna-Mäkelä
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